FUNDING_MECHANISM: SBIR-STTR RPGS

NIH_SPENDING_CATS: Biotechnology;Immunization;Infectious Diseases;Malaria;Malaria Vaccine;Orphan Drug;Prevention;Rare Diseases;Vaccine Related;Vector-Borne Diseases

ORG_CITY: ROCKVILLE

ORG_NAME: SANARIA, INC.

PHR: Project narrative In our screens to identify an adjuvant that can promote dose sparing and prolong duration of protection with an attenuated malaria vaccine, a novel glycolipid, 7DW8-5 that binds CD1d, and stimulates iNKT cells, was the only agent over several TLR ligands tested, to demonstrate significant enhancement in a mouse malaria model. We propose further pre-clinical characterization of adjuvant activity in mice and primates, to support its inclusion with Sanaria’s radiation-attenuated PfSPZ Vaccine in order to significantly enhance vaccine potency, efficacy and feasibility of use.

PI_NAMEs: CHAKRAVARTY, SUMANA ;HOFFMAN, STEPHEN LEV (contact)

PROGRAM_OFFICER_NAME: MO, ANNIE X  Y

PROJECT_TERMS: Acceleration;Adjuvant;Affinity;analog;Antigens;Attenuated;Attenuated Vaccines;Binding;Biodistribution;Biological Assay;Biological Markers;biomarker discovery;CCL20 gene;CD8-Positive T-Lymphocytes;Cells;Cellular Immunity;cellular targeting;Chemicals;Chemoprophylaxis;Child;child bearing;Chloroquine;Clinic;Clinical;clinical implementation;clinical lot;Clinical Protocols;Clinical Trials;Coculture Techniques;Combined Vaccines;comparative;Contracts;cost effective;Cryopreservation;Cyclic GMP;design;Development;Dose;efficacy evaluation;efficacy outcomes;efficacy study;Formulation;Glycolipids;Goals;Human;Immune response;Immune system;Immunity;Immunization;Immunization Programs;Immunization Schedule;Immunize;immunogenicity;Immunologic Markers;improved;In Vitro;in vivo;Inbred Mouse;Inbreeding;Infection;Legal patent;Licensing;Ligands;Liver;Logistics;Lymphocyte;Macaca mulatta;Macaca nemestrina;Malaria;malaria infection;Malaria prevention;Malaria Vaccines;manufacture;Mass Vaccinations;Methodology;Methods;Modeling;mouse model;Mus;nonhuman primate;novel;Outcome;Parasites;permissiveness;Pilot Projects;Plasmodium falciparum;Plasmodium falciparum vaccine;Positioning Attribute;pre-clinical;pre-Investigational New Drug meeting;preclinical evaluation;preclinical study;Preparation;Primates;Prophylactic treatment;protective efficacy;Quality Control;Radiation;reconstitution;Regimen;research clinical testing;Route;Safety;Seasons;Speed;Sporozoites;Sterility;T cell response;T-Lymphocyte;Testing;Toxic effect;Toxicology;Vaccinated;Vaccination;vaccine efficacy;Vaccines;Venous;Woman

PROJECT_TITLE: A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-AIDC-P(11)]


ADMINISTERING_IC: AG

ARRA_FUNDED: N

ED_INST_TYPE: SCHOOLS OF MEDICINE

FUNDING_MECHANISM: NON-SBIR/STTR RPGS

IC_NAME: NATIONAL INSTITUTE ON AGING

NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Behavioral and Social Science;Biotechnology;Brain Disorders;Clinical Research;Clinical Trials and Supportive Activities;Dementia;Gene Therapy;Gene Therapy Clinical Trials;Genetics;Neurodegenerative;Neurosciences

ORG_CITY: LA JOLLA

ORG_COUNTRY: UNITED STATES

ORG_DEPT: NEUROSCIENCES

ORG_FIPS: US

ORG_NAME: UNIVERSITY OF CALIFORNIA, SAN DIEGO

ORG_STATE: CA

PHR: Project Narrative: We propose to conduct a first-in-human clinical trial of BDNF gene therapy in Alzheimer’s disease. BDNF (“Brain Derived Neurotrophic Factor”) builds new synapses in the brain, prevents cell death and stimulates neuronal function. It offers the potential to slow or even reverse cognitive decline in Alzheimer’s disease.

PI_NAMEs: TUSZYNSKI, MARK H. (contact)

PROGRAM_OFFICER_NAME: CLARKE, AKANNI YAO

PROJECT_TERMS: Alzheimer's Disease;Alzheimer's disease model;Alzheimer's disease patient;Alzheimer's disease therapy;Amyloid;Amyloid beta-Protein;Animal Experiments;Animal Model;Area;Autopsy;Biochemical;Biodistribution;Biological;Biological Markers;Brain;brain-derived growth factor;Brain-Derived Neurotrophic Factor;Cell Death;Cessation of life;Clinic;Clinical;clinical research site;clinical trial protocol;Clinical Trials;Cognitive;cognitive benefits;cognitive function;cohort;Collaborations;Combined Modality Therapy;Conduct Clinical Trials;Convection;Data;Development;Disease;Disease Progression;Dose;efficacy study;Enrollment;entorhinal cortex;Exhibits;first-in-human;fluorodeoxyglucose;fluorodeoxyglucose positron emission tomography;Future;Gene Delivery;gene replacement;gene therapy;Gene therapy trial;Gene Transfer;Genes;Growth Factor;Hippocampus;Human;imaging biomarker;Impaired cognition;improved;interest;Intervention;Learning;Leber's Hereditary Optic Neuropathy;Life;Macaca mulatta;Magnetic Resonance Imaging;Measures;Mediating;Medical;Memory;Memory Disorders;Memory Loss;Methodology;Methods;mild cognitive impairment;Molecular;Mus;Nerve Degeneration;Nervous System;neural circuit;neuroimaging;neuron loss;Neurons;neuroprotection;nonhuman primate;Ohio;Outcome Measure;Parkinson Disease;Pathology;Patients;Phase I Clinical Trials;phase II trial;prevent;primary outcome;Primates;Procedures;programs;Proteins;Quality of life;Rattus;recruit;Research;response;Safety;safety assessment;Serotyping;Serum;Short-Term Memory;Spinal Muscular Atrophy;Standardization;Synapses;tau Proteins;Technology;Testing;Therapeutic Effect;Time;Toxic effect;trafficking;Translating;Universities;vector;Vision;Work

PROJECT_TITLE: A Clinical Trial of AAV2-BDNF Gene Therapy in Alzheimer's Disease


ADMINISTERING_IC: MH

IC_NAME: NATIONAL INSTITUTE OF MENTAL HEALTH

NIH_SPENDING_CATS: Aging;Basic Behavioral and Social Science;Behavioral and Social Science;Biomedical Imaging;Brain Disorders;Clinical Research;Clinical Trials and Supportive Activities;Depression;Major Depressive Disorder;Mental Health;Mental Illness;Neurosciences;Serious Mental Illness

ORG_CITY: NASHVILLE

ORG_NAME: VANDERBILT UNIVERSITY MEDICAL CENTER

ORG_STATE: TN

PHR: PROJECT NARRATIVE Depression in older adults is characterized by poor motivation, cognitive deficits, and mobility impairment. Dopamine is a key neurochemical basis underlying all of these processes, but its precise contributions to the deficits seen in late-life depression are poorly understood. This study will comprehensively characterize dopaminergic dysfunction in Late-Life Depression and determine the degree to which it responds to pharmacologic modulation with levodopa.

PI_NAMEs: TAYLOR, WARREN D (contact)

PROGRAM_OFFICER_NAME: LYONS, ELIZABETH ANNE

PROJECT_TERMS: Academic Medical Centers;Address;Age;age effect;age related;age related changes;Aging;Behavior;Behavior assessment;behavior measurement;Behavioral;Behavioral Symptoms;Binding;Blood Vessels;Brain;cerebral atrophy;Clinical;Clinical assessments;Cognition;Cognitive;Cognitive deficits;cognitive system;cognitive testing;Corpus striatum structure;cost;Crossover Design;Data;Data Set;Decision Making;Depressed mood;Depressive disorder;Development;Disabling;Dopamine;Dopamine D2 Receptor;Dopamine Receptor;dopamine system;dopamine transporter;Elderly;Enrollment;Evaluation;Exclusion;Executive Dysfunction;Exhibits;Expenditure;Functional disorder;Functional Magnetic Resonance Imaging;Future;Gait abnormality;Gait speed;Gender;geriatric depression;Goals;hedonic;Impairment;improved;Inflammatory;inflammatory marker;innovation;Intervention;Ischemia;Levodopa;Magnetic Resonance Imaging;Measurement;Measures;Mental Depression;Midbrain structure;middle age;Mobility decline;Modeling;Molecular;Moods;Motivation;Motor;Movement;multimodality;neural;neurochemistry;Neurocognitive;neuromelanin;Neuropsychology;new therapeutic target;New York;normal aging;novel;older adult;Outcome;Outpatients;pars compacta;Participant;Pathway interactions;Patient Self-Report;Performance;personalized medicine;pharmacologic;Phase;Phenotype;Physical Function;Physical Performance;Placebos;Positive Valence;Positron-Emission Tomography;Prefrontal Cortex;Process;processing speed;Publishing;Randomized;receptor density;Research;Research Domain Criteria;response;reward processing;Rewards;sensorimotor system;Signal Transduction;Site;Structure;Substantia nigra structure;System;Testing;therapy development;transmission process;Universities;willingness;Work;young adult

PROJECT_TITLE: 2/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)

STUDY_SECTION: NPAS

STUDY_SECTION_NAME: Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section[NPAS]


ADMINISTERING_IC: AI

IC_NAME: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

NIH_SPENDING_CATS: Biodefense and Related Countermeasures;Biotechnology;Clinical Research;Coronaviruses;Coronaviruses Vaccines;Emerging Infectious Diseases;Immunization;Infectious Diseases;Prevention;Vaccine Related

ORG_CITY: BOSTON

ORG_NAME: BRIGHAM AND WOMEN'S HOSPITAL

ORG_STATE: MA

PHR: NARRATIVE Antibodies specific for pathogenic threats can provide immediate protection from infectious disease but longevity of an antibody responses after vaccination or infection can be highly variable. The proposed research is relevant to public health because it will illuminate factors that influence antibody durability of immune responses. This is expected to have a substantial impact as it will inform vaccine design for the current as well as future infectious threats.

PI_NAMEs: WESEMANN, DUANE R. (contact)

PROGRAM_OFFICER_NAME: CASTLEMAN, MORIAH JOVITA

PROJECT_TERMS: Affinity;Animal Model;Antibodies;Antibody Response;antigen binding;Antigens;Attenuated Vaccines;Automobile Driving;B cell repertoire;B-Cell Activation;B-Lymphocytes;Binding;Cell Communication;cohort;Communicable Diseases;Coronavirus;COVID-19;COVID-19 pandemic;cross reactivity;Cues;Data;Disease;Dose;Engineering;Epitopes;Evolution;Frequencies;Future;Generations;Goals;Human;Human Papilloma Virus Vaccine;Immune;Immune response;Immune system;Immunity;Immunoglobulin G;Immunoglobulin Somatic Hypermutation;Immunoglobulin-Secreting Cells;Immunoglobulins;Immunologics;Immunology;improved;Infection;insight;Invaded;Light;Link;Longevity;Lymphocyte;Memory;Memory B-Lymphocyte;Modernization;Mus;Mutation;neutralizing antibody;particle;pathogen;Pathogenicity;plasma cell differentiation;Plasma Cells;polyclonal antibody;post SARS-CoV-2 infection;prophylactic;protective efficacy;Proteins;Public Health;Recovery;Research;response;RNA vaccination;Sampling;SARS-CoV-2 antibody;SARS-CoV-2 infection;Somatic Mutation;Speed;Structure of germinal center of lymph node;System;T-Lymphocyte;Testing;Time;time interval;Vaccination;vaccine access;Vaccine Design;vaccine strategy;Vaccinee;Vaccines;Variant;Viral;Virus;Work

PROJECT_TITLE: Antibody Durability Dynamics

STUDY_SECTION: CMIA

STUDY_SECTION_NAME: Cellular and Molecular Immunology - A Study Section[CMIA]


ADMINISTERING_IC: CA

IC_NAME: NATIONAL CANCER INSTITUTE

NIH_SPENDING_CATS: Cancer;Hematology;Lymphatic Research;Lymphoma;Precision Medicine;Prevention;Rare Diseases;Skin Cancer

ORG_CITY: NEW YORK

ORG_NAME: SLOAN-KETTERING INST CAN RESEARCH

ORG_STATE: NY

PHR: Project Narrative Cutaneous T-cell lymphomas (CTCL) are a common form of skin cancer with highly variable clinical behavior and without robust tests that can be used for unequivocal diagnosis or predict who will have aggressive disease or response to therapy. Sézary Syndrome is an aggressive form of CTCL with poor outcomes, and our laboratory recently developed a strategy to identify histone post-translational marks that will offer a robust strategy for provide better diagnostic tools and predict response to histone deacetylase inhibitors. The studies in this proposal will lead to development of simple blood-based assays that will improve early detection and predict response to therapies.

PI_NAMEs: ELENITOBA-JOHNSON, KOJO S. J. (contact)

PROGRAM_OFFICER_NAME: MCKEE, TAWNYA C

PROJECT_TERMS: accurate diagnosis;Address;Aggressive Clinical Course;Antineoplastic Agents;Behavior;Biological Assay;Biological Markers;Biological Process;Blood;CD4 Positive T Lymphocytes;Chemicals;CLIA certified;Clinical;cohort;Credentialing;Cutaneous T-cell lymphoma;Data;Detection;Development;Diagnosis;Diagnostic;diagnostic accuracy;diagnostic biomarker;diagnostic criteria;diagnostic tool;Disease;Early Diagnosis;Exhibits;Flow Cytometry;Gene Expression;Goals;Histone Code;Histone Deacetylase Inhibitor;Histone Deacetylation;Histones;improved;improved outcome;indexing;Individual;Indolent;Infiltration;innovation;Laboratories;Learning;Life Expectancy;Lymphoid;Malignant Neoplasms;Mass Spectrum Analysis;Measurement;Measures;Modeling;Modification;mortality;Mycosis Fungoides;Nature;Neoplasm Circulating Cells;neoplastic cell;novel;Outcome;Pathogenesis;patient response;Patients;Peripheral;Pharmaceutical Preparations;predicting response;Prediction of Response to Therapy;predictive marker;Prospective cohort;Resources;response;Retrospective cohort;Sampling;Sezary Syndrome;Skin;Skin Cancer;skin lesion;Staging;Subcategory;T-Cell Lymphoma;targeted treatment;Testing;Therapeutic Effect;Time;treatment response;Tumor Burden;Validation;Variant

PROJECT_TITLE: Epiproteomics of Sezary Syndrome

STUDY_SECTION: CBSS

STUDY_SECTION_NAME: Cancer Biomarkers Study Section[CBSS]


NIH_SPENDING_CATS: Biotechnology;Breast Cancer;Cancer;Women's Health Research

ORG_CITY: CHARLESTON

ORG_DEPT: BIOCHEMISTRY

ORG_NAME: MEDICAL UNIVERSITY OF SOUTH CAROLINA

ORG_STATE: SC

PHR: PROJECT NARRATIVE The proposed project is relevant to public health because it represents novel and clinically-relevant potential therapeutic strategy i.e., targeting TACC3, to inhibit tumor growth and metastasis in breast cancer patients with centrosome amplification, representing a highly aggressive patient subgroup with worse survival and a high risk of developing distant metastasis. Once TACC3 is established as a potent target pre-clinically using our novel inhibitor in state-of-the-art experimental models, there is potential for significant advance in the treatment of highly aggressive breast and potentially other tumors with centrosome amplification. Thus, the proposed project is relevant to the part of the NIH’s mission that pertains to reducing illness and disability.

PI_NAMEs: SAHIN, OZGUR  (contact)

PROGRAM_OFFICER_NAME: AULT, GRACE S

PROJECT_TERMS: 4T1;Acetylation;advanced breast cancer;aggressive breast cancer;Apoptosis;Apoptotic;BCL2 gene;Binding Proteins;Biological Assay;Breast;Breast Cancer Model;Breast Cancer Patient;cancer cell;CDC2 gene;Cell Death;Cell Death Induction;Cell division;Cell Line;cell motility;Cell Polarity;Cells;Centrosome;Clathrin;Clinic;clinically relevant;Clustered Regularly Interspaced Short Palindromic Repeats;CRISPR/Cas technology;Data;Death Rate;Defect;disability;Distant Metastasis;Experimental Models;Extracellular Matrix;Focal Adhesions;Genetic;Goals;Golgi Apparatus;Growth;HDAC2 gene;High Prevalence;high risk;Immunocompetent;Immunofluorescence Immunologic;improved;In Vitro;in vivo;inhibitor;innovation;Integrins;Interphase;Interphase Cell;Invaded;Knock-out;Legal patent;live cell imaging;Lung;Malignant Breast Neoplasm;Malignant Neoplasms;Mammary Neoplasms;Mass Spectrum Analysis;Mediating;Methods;Microtubules;migration;Mission;Mitosis;Mitotic;Mitotic spindle;Modeling;Molecular;Motility;Mouse Mammary Tumor Virus;mouse model;mutant;Mutation;Neoplasm Metastasis;Noninfiltrating Intraductal Carcinoma;Normal Cell;novel;Organoids;Output;Ovarian;overexpression;patient derived xenograft model;patient subsets;Patient-Focused Outcomes;Phenotype;Physiological;polarized cell;polyoma middle tumor antigen;pre-clinical;prevent;Primary Neoplasm;Prognosis;Prostate;Proteins;Public Health;Research;Role;success;Testing;Therapeutic;therapeutic target;three dimensional cell culture;Toxic effect;TP53 gene;trafficking;Transgenic Mice;triple-negative invasive breast carcinoma;Tubulin;tumor;tumor growth;tumor progression;Tumor-Derived;United States National Institutes of Health;Xenograft procedure

PROJECT_TITLE: Inhibiting tumor growth and metastasis in highly aggressive breast cancers with centrosome amplification

STUDY_SECTION_NAME: Mechanisms of Cancer Therapeutics - 2 Study Section[MCT2]


NIH_SPENDING_CATS: Brain Disorders;Breast Cancer;Cancer;Immunotherapy;Neurosciences;Women's Health Research

ORG_CITY: IRVINE

ORG_DEPT: PHYSIOLOGY

ORG_NAME: UNIVERSITY OF CALIFORNIA-IRVINE

PHR: Project Narrative Although the immune system has emerged as an effective therapeutic target to control tumor growth and metastasis of peripheral cancers, little is known about the immune response to breast cancer brain metastasis and why it ultimately fails to control CNS metastasis in breast cancer patients. We have utilized single-cell RNA-sequencing to find that microglia, the main immune cell populations of the CNS, display a dramatic and heterogeneous pro-inflammatory response to brain metastasis and are critical to suppress metastatic outgrowth in the CNS. In this study, we will determine the mechanisms underlying microglia-mediated metastasis suppression, by testing whether they are critical to recruit peripheral anti-tumor immunity and/or present antigen for local stimulation of T cell responses.

PI_NAMEs: LAWSON, DEVON A. (contact)

PROGRAM_OFFICER_NAME: KUO, LILLIAN S

PROJECT_TERMS: Ablation;access restrictions;Acute;Antigen Presentation;Antigen Presentation Pathway;Attenuated;Biological Assay;Blood - brain barrier anatomy;Bone Marrow;Brain;Breast Cancer Model;Breast Cancer Patient;CD8-Positive T-Lymphocytes;Cells;Central Nervous System;chemokine;Chemotactic Factors;Chemotaxis;Clinical;cytotoxic;cytotoxicity;Development;Disease;drug standard;Genes;Immune;immune resistance;Immune response;Immune system;Immunity;Immunofluorescence Immunologic;Immunotherapeutic agent;improved;In Situ;In Vitro;in vivo;Infection;Infiltration;Inflammation;Inflammatory;Inflammatory Response;insight;Knock-out;Lesion;Macrophage;Malignant Breast Neoplasm;Malignant Neoplasms;Mediating;Metastasis Suppression;Metastatic malignant neoplasm to brain;Metastatic Neoplasm to the Central Nervous System;Microglia;migration;Modeling;monocyte;Myeloid Cells;Neoplasm Metastasis;Nervous System Trauma;novel therapeutics;Patients;Peripheral;Phagocytes;pharmacologic;Phenotype;Play;Population;prevent;recruit;Research;response;Role;single cell analysis;single-cell RNA sequencing;Survival Rate;T cell infiltration;T cell response;T-Cell Activation;T-Lymphocyte;Testing;Therapeutic;therapeutic target;therapeutically effective;Time;Tissues;tumor growth;Tumor Immunity;tumorigenic;Work

PROJECT_TITLE: Inflammatory microenvironment in brain metastasis

STUDY_SECTION: TME

STUDY_SECTION_NAME: Tumor Microenvironment Study Section[TME]


NIH_SPENDING_CATS: Biotechnology;Immunization;Infant Mortality;Infectious Diseases;Pediatric;Perinatal Period - Conditions Originating in Perinatal Period;Preterm, Low Birth Weight and Health of the Newborn;Prevention;Vaccine Related

ORG_CITY: SAINT LOUIS

ORG_NAME: VAXNEWMO, LLC

ORG_STATE: MO

PHR: PROJECT NARRATIVE The goal of this project is to further development of a bioconjugate vaccine against Streptococcus agalactiae, commonly referred to as Group B Streptococcus (GBS). The key objectives of the Phase II project are to optimize vaccine production and purification processes, perform dose-escalation studies in mice to evaluate immunogenicity and functional antibody responses, and assess vaccine efficacy using an established neonatal pup survival model.

PI_NAMEs: HARDING, CHRISTIAN  (contact)

PROGRAM_OFFICER_NAME: GU, XIN-XING

PROJECT_TERMS: Amino Acid Sequence;Antibiotic Prophylaxis;Antibodies;Antibody Response;Awareness;Bacterial Polysaccharides;Binding;Biological Assay;bioprocess;Bioreactors;Birth;Capital;Carrier Proteins;Cells;Cessation of life;chemical conjugate;Chemistry;Chimeric Proteins;Clinical;Clinical Research;Complex;Conjugate Vaccines;cost;Country;Data;Development;Disease;Dose;early onset;efficacy evaluation;Engineering;Ensure;Enzyme-Linked Immunosorbent Assay;Enzymes;Epitopes;Escherichia coli;Event;Fetus;flasks;Formulation;Funding;glycosylation;Goals;Histidine;Human;Immune;immunogenic;immunogenicity;Impairment;improved;in vivo;Incidence;Income;Industrialization;interest;intrapartum;Late-Onset Disorder;Legal patent;Life;Link;low and middle-income countries;low income country;manufacture;Manufacturer;Marketing;Maternal antibody;Mediating;Methods;Microbe;Modeling;Mothers;Mus;Neonatal;Neonatal meningitis;neonatal sepsis;Neurologic;Newborn Infant;Onset of illness;pathogen;pathogenic bacteria;Pharmaceutical Preparations;Phase;Polysaccharides;Population;Positioning Attribute;pre-IND studies;prevent;Process;Production;programs;Protein Engineering;prototype;pup;Recombinants;recruit;research and development;Risk;Risk Reduction;Serotyping;Site;Small Business Innovation Research Grant;stillbirth;Streptococcal Infections;Streptococcal Vaccines;Streptococcus Group B;Survivors;System;Technology;Therapeutic Intervention;Translating;treatment strategy;Vaccinated;vaccine development;vaccine efficacy;vaccine evaluation;Vaccine Production;vaccine strategy;Vaccines;virtual;World Health Organization

PROJECT_TITLE: Development of a Group B Streptococcus bioconjugate vaccine

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-DCAI-U(11)]


NIH_SPENDING_CATS: Cancer;Clinical Research;Clinical Trials and Supportive Activities;Comparative Effectiveness Research;Cost Effectiveness Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Pediatric;Prevention;Rural Health;Social Determinants of Health

ORG_CITY: SALT LAKE CITY

ORG_DEPT: PEDIATRICS

ORG_NAME: UNIVERSITY OF UTAH

ORG_STATE: UT

PHR: NARRATIVE We propose a randomized controlled trial to test a 4-session virtual health insurance navigation intervention that will increase knowledge about health insurance, reduce financial burden, and improve surveillance for recurrence among 300 young adult cancer survivors ages 26 to 39. We will combine self-reported survey data with electronic health records and claims data to examine the trial outcomes and efficacy. We will also conduct an economic evaluation using cost-effectiveness and budget impact analyses, to establish the sustainability of the intervention at improving outcomes of young adult survivors through increasing their health insurance knowledge and decreasing their financial burden.

PI_NAMEs: KIRCHHOFF, ANNE C (contact);PARK, ELYSE R.

PROGRAM_OFFICER_NAME: DAVIDOFF, AMY

PROJECT_TERMS: Address;Adult;Affect;Aftercare;Age;arm;barrier to care;Behavioral Model;Behavioral Sciences;Breast;budget impact;cancer care;cancer recurrence;Cancer Survivor;cancer survivorship care;cancer therapy;Caring;chemotherapy;childhood cancer survivor;Clinics and Hospitals;Colorectal Cancer;comparison control;cost;cost effectiveness;Cost Effectiveness Analysis;Data;data infrastructure;data integration;design;Diagnosis;economic evaluation;efficacy evaluation;efficacy testing;Electronic Health Record;Enrollment;Ethnic Origin;evidence base;experience;Financial Hardship;financial toxicity;follow-up;Future;Goals;Guidelines;health application;Health Insurance;health service use;Health Services Accessibility;Healthcare;Healthcare Systems;Hispanic;Hospitals;improved;improved outcome;Insurance;Intervention;intervention effect;Interview;Knowledge;Latinx;Link;literacy;Location;Lymphoma;Malignant Neoplasms;Medical Care Costs;National Cancer Institute;National Comprehensive Cancer Network;oncology service;Operative Surgical Procedures;Outcome;Parents;Participant;Pathway interactions;patient navigation;Patient Self-Report;Patient-Focused Outcomes;pilot test;pilot trial;Policies;Population;primary outcome;programs;Radiation;Randomized;randomized trial;Randomized, Controlled Trials;Recommendation;recruit;Recurrence;Reporting;Resources;Rural;rurality;Sampling;Sarcoma;Schools;secondary outcome;Services;Subgroup;success;Surveys;Survivors;survivorship;Testing;Time;tool;treatment arm;treatment as usual;Treatment Cost;United States;Universities;Utah;virtual health;virtual patient;Work;young adult

PROJECT_TITLE: A Randomized Controlled Trial to Improve Health Insurance Literacy and Surveillance among Young Adult Cancer Survivors

STUDY_SECTION: ICSC

STUDY_SECTION_NAME: Interdisciplinary Clinical Care in Specialty Care Settings Study Section[ICSC]


NIH_SPENDING_CATS: Aging;Cancer;Clinical Research;Immunotherapy;Nutrition;Obesity;Patient Safety;Precision Medicine;Prevention;Sarcopenia;Urologic Diseases

ORG_CITY: Oakland

ORG_NAME: KAISER FOUNDATION RESEARCH INSTITUTE

PHR: Project Narrative Bladder cancer is one of the top ten most common cancers in the U.S., with 75% diagnosed with non-muscle invasive disease (NMIBC) and up to 70% of which experience recurrence, making it one of the most expensive cancers to treat per patient. Body composition, which is the amount of fat and muscle tissue, affects the inflammatory and immune environments, and thus can possibly influence treatment response and disease prognosis in NMIBC patients. In a prospective study of 1,472 NMIBC patients, we will conduct a comprehensive study of body composition, inflammation, and immunity to evaluate their impact on treatment and prognosis outcomes over eight years of follow-up.

PI_NAMEs: KWAN, MARILYN L (contact);TANG, LI

PROGRAM_OFFICER_NAME: FILIPSKI, KELLY

PROJECT_TERMS: Address;Adipose tissue;Adverse effects;Adverse event;Affect;Age;age related;age-related muscle loss;Bacillus Calmette-Guerin Therapy;BCG Live;Biological Markers;Body Composition;Body mass index;cancer diagnosis;cancer epidemiology;Cancer Patient;Cancer Prognosis;cancer recurrence;Cancer Survivor;Chronic;Clinical;clinical care;Clinical Data;Data;Diagnosis;Diet;Disease;Disease Outcome;disease prognosis;effective therapy;Environment;experience;Failure;Fatty acid glycerol esters;follow-up;Genetic;high risk;Immune;Immune response;Immunity;Immunologic Markers;Immunosuppression;Immunotherapy;improved;individualized medicine;Infiltration;Inflammation;Inflammatory;intravesical;Intravesical Administration;Investigation;Life Style;lifestyle factors;Link;Malignant neoplasm of urinary bladder;Malignant Neoplasms;Managed Care;Measures;Mediating;Modeling;mortality;Muscle;muscle form;muscle invasive bladder cancer;Newly Diagnosed;non-muscle invasive bladder cancer;Obesity;older patient;Outcome;participant enrollment;patient stratification;Patients;Performance;Phenotype;Physical activity;prevent;Prognosis;prognostic;Prognostic Factor;Prognostic Marker;progression risk;Prospective cohort;Prospective Studies;Prospective, cohort study;Recurrence;Recurrent disease;Research;Risk;risk stratification;Role;sarcopenia;sarcopenic obesity;Scanning;sex;Sex Differences;Shapes;Skeletal Muscle;skeletal muscle wasting;Smoking;subcutaneous;success;survivorship;System;Testing;Time;Treatment Failure;Treatment outcome;treatment planning;treatment response;tumor;tumor progression;Visceral;X-Ray Computed Tomography

PROJECT_TITLE: Impact of Body Composition and Related Inflammatory and Immune States on Prognosis of Non-Muscle Invasive Bladder Cancer


ADMINISTERING_IC: HL

FUNDING_MECHANISM: TRAINING, INDIVIDUAL

IC_NAME: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

NIH_SPENDING_CATS: Diabetes;Infectious Diseases;Lung;Nutrition;Obesity;Pneumonia;Pneumonia and Influenza

ORG_CITY: ANN ARBOR

ORG_DEPT: MICROBIOLOGY/IMMUN/VIROLOGY

ORG_NAME: UNIVERSITY OF MICHIGAN AT ANN ARBOR

ORG_STATE: MI

PHR: Project Narrative Patients with T2D are at increased risk for greater morbidity and mortality due to bacterial pneumonia; therefore it is critical to understand how immune responses are altered due to obesity and T2D. We have identified that innate immune cells such as alveolar macrophages and neutrophils have inherent functional and recruitment defects during obesity. This project aims to understand these defects and how they contribute to increased disease during pneumonia caused by Pseudomonas aeruginosa, which will provide insight that may lead to advances in treatments for patients with T2D diagnosed with respiratory infections.

PI_NAMEs: ENTRUP, GABRIELLE  (contact)

PROGRAM_OFFICER_NAME: LU, JINING

PROJECT_TERMS: 2019-nCoV;Adipose tissue;Adult;Affect;Alveolar Macrophages;Animals;Anti-Bacterial Agents;Antibacterial Response;Bacteria;Bacterial Infections;Bacterial Pneumonia;bactericide;Biological Assay;Blood;Blood specimen;Bone Marrow;burden of illness;Cell Physiology;Cells;chemokine;Chronic;Clinical;Complication;cytokine;Data;Defect;Diabetes Mellitus;diabetic;Diabetic mouse;diabetic wound healing;Diagnosis;diet-induced obesity;differential expression;Dinoprostone;Disease;Exhibits;Experimental Designs;experimental study;Failure;Female;Functional impairment;Gene Expression;Generations;Goals;Health;Heart Diseases;Hematopoietic;Host Defense;Hour;Human;Immune;Immune response;Immune signaling;Immune system;immunoregulation;Impairment;improved;improved outcome;Infection;Inflammation;Inflammatory;innate immune function;innovation;insight;Insulin Resistance;Kinetics;Knowledge;Link;Lung;lung histology;Macrophage;male;Malignant Neoplasms;Measures;Metabolic;Metabolic Diseases;Metabolism;microbial;Modeling;Molecular;Morbidity - disease rate;mortality;Mus;Myeloid Cells;neutrophil;Neutrophil Infiltration;Nitric Oxide;Non-Insulin-Dependent Diabetes Mellitus;Nonesterified Fatty Acids;novel;Obese Mice;obese patients;Obesity;Organ;Overweight;oxidative damage;Patient-Focused Outcomes;Patients;Persons;Phagocytes;Phagocytosis;Population;Predisposition;Production;Pseudomonas aeruginosa;Pseudomonas aeruginosa infection;Pseudomonas aeruginosa pneumonia;Public Health;Publishing;pulmonary function;recruit;Regulation;respiratory;Respiratory Tract Infections;Risk;Scientist;Sepsis;sex as a biological variable;Signal Transduction;Site;Skin Tissue;soft tissue;Spleen;stem;Stroke;Symptoms;Testing;Thinness;Tissues;TLR4 gene;Training;Transcription Alteration;transcriptome sequencing;Virus;Virus Diseases;Work;wound

PROJECT_TITLE: Obesity Inhibits Innate Lung Bactericidal Functions


ADMINISTERING_IC: NS

FUNDING_MECHANISM: OTHER RESEARCH-RELATED

IC_NAME: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

ORG_DEPT: NEUROLOGY

PHR: PROJECT NARRATIVE Epilepsy is a debilitating chronic disease that affects over 3 million people in the United States, many of whom have ongoing seizures despite optimized treatments. I propose to determine the mechanism and consequences of a dysfunctional neuronal circuit that I have identified in a genetic mouse model of epilepsy, using cutting-edge techniques for the manipulation and recording of defined neurons within the brain. This mentored career development award will fill gaps in my scientific and technical knowledge and skill set, preparing me for a career devoted to development of novel, mechanistic, circuit-based therapies in preclinical experimental models of epilepsy that can be translated to patient care.

PI_NAMEs: MATTIS, JOANNA H (contact)

PROGRAM_OFFICER_NAME: REZAIZADEH, KAVON PAUL

PROJECT_TERMS: Action Potentials;Affect;Award;Biomedical Research;Board Certification;Brain;Calcium;career;career development;Cells;Choking;Chronic Disease;Clinic;Clinical;Communities;Data;dentate gyrus;Department chair;design;detector;Development;Development Plans;Disease;Disparate;Doctor of Philosophy;Electrophysiology (science);Ensure;entorhinal cortex;Environment;Epilepsy;Etiology;Exhibits;Experimental Models;experimental study;Faculty;Fellowship;Focal Seizure;Functional disorder;Funding;Future;gamma-Aminobutyric Acid;Generations;Genes;Genetic;Genetic Models;Glean;Goals;granule cell;Head;Hippocampus;Hyperthermia;Image;imaging modality;Impairment;in vivo;Injury;insight;Institution;instructor;Interneurons;Intractable Epilepsy;Investigation;K-Series Research Career Programs;Knowledge;Laboratories;Laboratory Research;Lead;Link;Measures;Mediating;member;Mentors;Mentorship;Methods;Monitor;Motivation;mouse model;Mus;Mutation;National Institute of Neurological Disorders and Stroke;Neurologist;Neurology;neuronal circuitry;Neurons;Neurosciences;Neurosciences Research;new therapeutic target;novel;optogenetics;Outcome;Parvalbumins;patch clamp;Pathogenesis;Pathology;Patient Care;Patients;Pediatric Hospitals;Pennsylvania;Perforant Pathway;Persons;Philadelphia;Physicians;Physiology;Positioning Attribute;postsynaptic;pre-clinical;professor;recruit;Refractory;Research;Resources;response;Rodent Model;Role;Scientist;SCN1A protein;Seizures;Series;Signal Transduction;skills;Slice;Sodium Channel;Status Epilepticus;Synapses;targeted treatment;Techniques;Temporal Lobe;Temporal Lobe Epilepsy;Testing;therapy development;Training;Training Programs;Translating;treatment optimization;two-photon;United States;United States National Institutes of Health;University Hospitals;Whole-Cell Recordings

PROJECT_TITLE: Cortico-hippocampal circuit dysfunction in an Scn1a mouse model of epilepsy

STUDY_SECTION: NST

STUDY_SECTION_NAME: NST-1 Study Section[NST-1]


ADMINISTERING_IC: GM

IC_NAME: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

NIH_SPENDING_CATS: Genetics

ORG_DEPT: PHARMACOLOGY

PHR: Narrative/Public Health Relevance Statement  The splicing of genes is essential for normal cell function but can lead to many human diseases when performed incorrectly. The SRPKs are essential enzymes that play vital roles not only in splicing but also at the beginning of life where necessary changes in DNA are required upon fertilization of the egg. We will study the mechanisms that allow SRPKs to drive these essential biological functions.

PI_NAMEs: ADAMS, JOSEPH  (contact)

PROGRAM_OFFICER_NAME: CZAPLINSKI, KEVIN

PROJECT_TERMS: 5' Splice Site;Active Sites;Alzheimer's Disease;Area;Arginine;Ataxia;Automobile Driving;Beginning of Life;Binding;Binding Proteins;Biological;Biological Process;Biophysics;Cardiovascular Diseases;catalyst;Cell Nucleus;Cell Physiology;Cells;Cellular biology;Code;Complex;Confocal Microscopy;Cyclic AMP-Dependent Protein Kinases;Cytoplasm;design;Development;Dipeptides;Disease;DNA;Docking;Elements;Enzyme Kinetics;Enzymes;Event;Excision;experimental study;Fertilization;Gatekeeping;Genes;Genome;Genomic DNA;Genomics;Histones;human disease;Kinetics;Life;Malignant Neoplasms;Mass Spectrum Analysis;Messenger RNA;Modeling;Molecular Biology;mRNA Precursor;Mus;Muscular Dystrophies;Normal Cell;novel;Nuclear;Nuclear Translocation;Oocytes;Parkinsonian Disorders;Phase Transition;Phosphorylation;Phosphorylation Site;Phosphotransferases;Play;Process;protamine 1;Protamines;protein activation;Protein Family;protein function;Protein Kinase;Proteins;public health relevance;Reaction;Regulatory Pathway;release factor;Research Proposals;RNA;RNA Splicing;Role;scaffold;Serine;seryl-proline;Set protein;Signal Transduction;Spliced Genes;Spliceosome Assembly Pathway;Spliceosomes;STY kinase;Techniques;U1 Small Nuclear Ribonucleoprotein;Untranslated RNA;zygote

PROJECT_TITLE: Regulatory Pathways of SR Protein Kinases

STUDY_SECTION: MSFB

STUDY_SECTION_NAME: Macromolecular Structure and Function B Study Section[MSFB]


ADMINISTERING_IC: DK

FUNDING_MECHANISM: TRAINING, INSTITUTIONAL

IC_NAME: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES

NIH_SPENDING_CATS: Clinical Research;Digestive Diseases;Health Services

ORG_CITY: PHILADELPHIA

ORG_DEPT: INTERNAL MEDICINE/MEDICINE

ORG_NAME: UNIVERSITY OF PENNSYLVANIA

ORG_STATE: PA

PHR: PROJECT NARRATIVE  There is a major national shortage of qualified clinician scientists able to conduct rigorous gastrointestinal clinical research that is projected to increase in the next decade. Clinician scientists are needed to address pivotal questions regarding the etiology, treatment, public health impact, and optimal models for delivery of care for gastrointestinal diseases such as functional bowel disorders, inflammatory bowel diseases, intestinal cancers, chronic liver disease, and pancreatitis. This training program addresses this shortage through the efforts of a distinguished, experienced, and committed program faculty.

PI_NAMEs: LEWIS, JAMES D (contact)

PROGRAM_OFFICER_NAME: SERRANO, KATRINA JANE

PROJECT_TITLE: Clinical Epidemiology Training in Gastroenterology


NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Behavioral and Social Science;Brain Disorders;Clinical Research;Dementia;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Neurodegenerative;Neurosciences;Rehabilitation;Social Determinants of Health

ORG_NAME: TEMPLE UNIV OF THE COMMONWEALTH

PHR: PROJECT NARRATIVE As the U.S. population of adults over age 65 increases and grows more diverse, highly sensitive, objective and automated measurement of functional abilities is needed to identify older adults at risk for cognitive decline and to advance our understanding of mild functional difficulties and disability. This proposal evaluates the utility of the Virtual Kitchen Challenge, a novel, portable, non-immersive, virtual reality task developed for the assessment of everyday function and characterization of functional difficulties in older adults with a range of cognitive abilities, including people with mild cognitive impairment and dementia.

PI_NAMEs: GIOVANNETTI, TANIA  (contact)

PROGRAM_OFFICER_NAME: KING, JONATHAN W

PROJECT_TERMS: academic standard;Activities of Daily Living;Address;Adult;Age;aged;Aging;Alzheimer's Disease;Alzheimer's disease related dementia;Assessment tool;Behavior;Belief;Benchmarking;Characteristics;Clinical;clinical application;clinical decision-making;Cognition;Cognitive;cognitive ability;Cognitive aging;cognitive testing;computer science;Computers;Consumption;Data;Dementia;demographics;design;disability;Economics;Education;Educational Status;Elderly;Ethnic Origin;expectation;functional status;Future;Goals;Guidelines;healthy aging;human old age (65+);Impaired cognition;Impairment;Individual;individual variation;informant;Intervention;Investigation;Longitudinal Studies;Masks;Measurement;Measures;men;Methods;mild cognitive impairment;Nature;Neuropsychology;novel;older adult;Older Population;Output;Participant;Performance;performance based measurement;Persons;Pharmaceutical Preparations;Population;portability;pre-clinical;Property;Psychometrics;Publishing;Questionnaires;Race;recruit;Regression Analysis;Reporting;Research;Risk;Sampling;sex;Socioeconomic Status;standard measure;Standardization;Testing;Time;tool;touchscreen;Validity and Reliability;virtual;virtual reality;Woman

PROJECT_TITLE: Assessing Everyday Function in Older Adults with the Virtual Kitchen

STUDY_SECTION: APDA

STUDY_SECTION_NAME: Adult Psychopathology and Disorders of Aging Study Section[APDA]


ADMINISTERING_IC: HD

IC_NAME: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

NIH_SPENDING_CATS: Contraception/Reproduction;Maternal Health;Maternal Morbidity and Mortality;Pediatric;Pregnancy;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Women's Health Research

ORG_CITY: KANSAS CITY

ORG_DEPT: PATHOLOGY

ORG_NAME: UNIVERSITY OF KANSAS MEDICAL CENTER

ORG_STATE: KS

PHR: Disorders of hemochorial placentation are a significant health issue and lead to pregnancy complications for mother and fetus. Invasive trophoblast cells are responsible for many necessary adaptations that occur at the uterine-placental interface. Identification of genes that regulate the invasive trophoblast cell lineage can provide insights into the development of diagnostics and therapeutic interventions for pregnancy-related disorders.

PI_NAMEs: SCOTT, REGAN LEIGH (contact)

PROGRAM_OFFICER_NAME: ILEKIS, JOHN V

PROJECT_TERMS: Address;Biological;biomedical scientist;Blood flow;candidate identification;Cell Differentiation process;Cell Lineage;Cell Proliferation;cell transformation;Cells;Communication;Critical Thinking;Cyclin-Dependent Kinase Inhibitor;Decidua;Development;diagnostic development;Disease;early pregnancy loss;Environment;Event;Exhibits;experimental study;Failure;Fetal Growth;Fetal Growth Retardation;Fetus;Genes;genome editing;Goals;Health;Hemochorial Placental Development;Human;In Vitro;in vivo;insight;Invaded;Kansas;Laboratories;loss of function;Medical center;Medicine;Mentors;Modeling;Molecular;Mothers;Mus;mutant;Nutrient;obstetrical complication;Oxygen;Pathogenesis;Pathology;Perinatal;Physiological;Physiology;Placenta;Placentation;Pre-Eclampsia;Pregnancy;Pregnancy Complications;pregnancy disorder;Premature Birth;Process;Rattus;Regulation;Reproduction;Research;Research Proposals;Rodent;Role;shear stress;single-cell RNA sequencing;Site;skills;Spiral Artery of the Endometrium;stem cell differentiation;System;Therapeutic Intervention;Tissues;Training;Transcript;transcriptomics;trophoblast;trophoblast stem cell;Universities;Uterus;Villous

PROJECT_TITLE: Establishment of the Uterine-Placental Interface

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-F06-V(20)L]


ED_INST_TYPE: SCHOOLS OF NURSING

NIH_SPENDING_CATS: Behavioral and Social Science;Breast Cancer;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Genetic Testing;Genetics;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Ovarian Cancer;Prevention;Racial and Ethnic Minority Health Research;Rare Diseases;Rehabilitation;Social Determinants of Health;Women's Health Research

ORG_CITY: BOCA RATON

ORG_NAME: FLORIDA ATLANTIC UNIVERSITY

ORG_STATE: FL

PHR: Project Narrative: The proposed research is relevant to public health because racially/ethnically diverse young women diagnosed with breast cancer at age ≤ 50 years, particularly Black and Hispanic/Latina women, suffer disproportionately from breast cancer health disparities and are under-represented in cancer genetics research. The objective of this career development award is to conduct a mixed methods study to gain contextual understanding of the experiences of young breast cancer survivors with regards to hereditary breast and ovarian cancer (HBOC) syndrome genetic testing, modify an existing web-based decision aid to meet the needs of young women diagnosed with breast cancer (survivors), add content related to sharing genetic test results to family members, and to conduct a pilot randomized controlled trial to determine the effect of the adapted decision- aid on reducing decisional conflict, increasing HBOC genetic testing, and promoting family risk communication among racially/ethnically diverse women. Upon successful completion of the proposed project, we expect our contribution to be an elucidation of factors that impact completion of HBOC multigene panel testing among diverse young breast cancer patients in South Florida and efficacy of a behavioral intervention for increasing multigene panel testing, cancer risk- reduction, and family risk communication.

PI_NAMEs: JONES, TARSHA  (contact)

PROGRAM_OFFICER_NAME: WALI, ANIL

PROJECT_TERMS: Active Learning;Address;Age;Area;Asian;Attitude;Behavior Therapy;Behavioral;Belief;biobehavior;Biological;Black race;black women;Blood;BRCA1 gene;BRCA2 gene;Breast Cancer Patient;Breast Cancer Prevention;Breast Cancer survivor;Cancer Control;cancer genetics;cancer health disparity;cancer risk;Cancer Survivorship;cancer survivorship care;Cancer-Predisposing Gene;career;cascade genetic testing;Clinical;clinical application;Communication;Conflict (Psychology);Cross-Sectional Studies;culturally appropriate intervention;Data;Decision Aid;Decision Making;Diagnosis;disease-causing mutation;Educational workshop;Ethics;ethnic disparity;ethnic diversity;ethnic minority;Ethnic Minority Women;Ethnic Population;experience;Exposure to;Failure;Family;Family history of;Family member;Feedback;Florida;Frequencies;Funding;Genes;Genetic;genetic panel test;Genetic Research;Genetic Risk;genetic risk assessment;genetic testing;Genomic medicine;Genomics;Goals;Grant;Health Disparities Research;health disparity;Hereditary Breast and Ovarian Cancer Syndrome;Hispanic;Individual;Inherited;Intervention;Intervention Studies;Interview;K-Series Research Career Programs;Knowledge;Latina;Leadership;Malignant Breast Neoplasm;Malignant neoplasm of ovary;Malignant Neoplasms;Measures;Mentored Research Scientist Development Award;Methodology;Methods;Minority;Minority Women;National Cancer Institute;National Comprehensive Cancer Network;Not Hispanic or Latino;Oncogenes;Oncology;Online Systems;PALB2 gene;Participant;Pathogenicity;Patient Education;Patients;Penetrance;Population;Population Intervention;Predisposition;primary outcome;Productivity;psychosocial;Public Health;racial disparity;racial diversity;racial minority;racial minority women;racial population;Randomized;Randomized, Controlled Trials;Recommendation;Recording of previous events;recruit;Reduce health disparities;Relative Risks;Research;Research Institute;Research Personnel;Risk;Risk Reduction;Risk Reduction Behavior;Science;Screening for cancer;secondary outcome;skills;Socioeconomic Status;Spanish;Spanish/English;Survivors;Test Result;Testing;Time;Training;Underserved Population;United States National Institutes of Health;United States Preventative Services Task Force;usability;user centered design;Variant;variant of unknown significance;web based decision aid;White Women;Woman;women's diagnosis;Writing;young woman

PROJECT_TITLE: Decision Support for Multigene Panel Testing and Family Risk Communication among Racially/Ethnically Diverse Young Breast Cancer Survivors

STUDY_SECTION: NCI

STUDY_SECTION_NAME: Career Development Study Section (J)[NCI-J]


NIH_SPENDING_CATS: Lung;Pulmonary Hypertension;Rare Diseases;Stem Cell Research;Stem Cell Research - Nonembryonic - Non-Human

ORG_CITY: CHICAGO

ORG_NAME: LURIE CHILDREN'S HOSPITAL OF CHICAGO

ORG_STATE: IL

PHR: Project Narrative The overall objective of the proposed studies is to determine the role of Mφ in the mechanisms of obliterative pulmonary vascular remodeling and severe PAH and thereby provide novel therapeutic approaches for treatment of PAH to inhibit/reverse obliterative vascular remodeling and promote survival.

PI_NAMEs: ZHAO, YOU-YANG  (contact)

PROGRAM_OFFICER_NAME: XIAO, LEI

PROJECT_TERMS: Angiogenic Factor;Animal Model;Attenuated;Blood Vessels;Bone Marrow;Bone Marrow Cells;Cell Lineage;Cell Proliferation;Cells;Cessation of life;Clinical;clinically relevant;Coculture Techniques;CSF1R gene;CXCR4 Receptors;Disease;druggable target;effective therapy;Endothelial Cells;Exhibits;G-Protein-Coupled Receptors;Genetic;Goals;Hematopoietic;Hypoxia;Hypoxia Inducible Factor;IGF1 gene;IGF1R gene;improved;inhibitor;Lesion;Lung;lung hypoxia;Macrophage;Mediating;Modeling;Molecular;Molecular Target;Morbidity - disease rate;mortality;mouse model;Mus;neointima formation;novel;novel therapeutic intervention;Pathogenesis;Pathogenicity;Patients;pharmacologic;PIK3CG gene;premature;Prevention;primary pulmonary hypertension;Procollagen-Proline Dioxygenase;Production;progenitor;Protein Isoforms;pulmonary arterial hypertension;pulmonary vascular remodeling;Pulmonary Vascular Resistance;Pulmonary vessels;Rattus;reconstitution;right ventricular failure;Role;Sampling;Signal Transduction;single-cell RNA sequencing;Smooth Muscle Myocytes;Sorting;Stromal Cell-Derived Factor 1;Structure of parenchyma of lung;Therapeutic;translational potential;Vascular remodeling

PROJECT_TITLE: Novel mechanisms of obliterative pulmonary vascular remodeling and severe pulmonary arterial hypertension

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-CVRS-G(03)]


ADMINISTERING_IC: DC

IC_NAME: NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS

ORG_CITY: Aurora

ORG_DEPT: OTOLARYNGOLOGY

ORG_NAME: UNIVERSITY OF COLORADO DENVER

ORG_STATE: CO

PHR: T32 Narrative The goal of this application is to provide research training in otolaryngology and its related sciences. Support is requested for in-depth training for 1) residents, 2) postdoctoral fellows, 3) predoctoral students and 4) short- term medical students.

PI_NAMEs: JENKINS, HERMAN A.;KINNAMON, SUE C. (contact)

PROGRAM_OFFICER_NAME: RIVERA-RENTAS, ALBERTO L

PROJECT_TITLE: Institutional Training in Otolaryngology Research


ADMINISTERING_IC: NR

IC_NAME: NATIONAL INSTITUTE OF NURSING RESEARCH

NIH_SPENDING_CATS: Behavioral and Social Science;Clinical Research;Coronaviruses;Coronaviruses Disparities and At-Risk Populations;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Prevention;Racial and Ethnic Minority Health Research;Social Determinants of Health

ORG_CITY: NEW HAVEN

ORG_DEPT: PUBLIC HEALTH & PREV MEDICINE

ORG_NAME: YALE UNIVERSITY

ORG_STATE: CT

PHR: Project Narrative Our project will estimate the impact of unprecedented pandemic era eviction-prevention policies on all cause- mortality, age-specific mortality, cause specific mortality, and racial and gender inequalities in these outcomes. We leverage: 1) a unique linkage between eviction filing data and mortality data to examine the impact of eviction on death rates during the pandemic 2) policy mapping data that comprehensively describes state and local eviction moratoria, data from the Treasury Department on the roll-out of emergency rental assistance, and a difference-and-difference framework to examine the impact of eviction prevention policies on county- level measures of mortality 3) qualitative data to examine lived experiences with these policies and pathways that connect them to mortality.

PI_NAMEs: HEPBURN, PETER ;KEENE, DANYA  (contact)

PROGRAM_OFFICER_NAME: GODETTE, DIONNE

PROJECT_TERMS: Address;Adult;Affect;Age;age related;Area;Automobile Driving;Black race;Buffers;Cause of Death;Censuses;Cessation of life;Chronic;Communities;cost;Country;County;Data;Data Collection;Data Files;Death Rate;early onset;Emergency Situation;ethnic difference;Ethnic Origin;Event;Excess Mortality;experience;Exposure to;Face;Female;Future;Gender;gender difference;Health;health equity;health inequalities;Healthcare;Hispanic;Housing;housing instability;Individual;Inequality;insight;Interview;Lifting;Link;Literature;Lived experience;Location;Maps;Measures;Methods;Morbidity - disease rate;mortality;Natural experiment;Occupations;Outcome;pandemic disease;pandemic impact;Pathway interactions;Patient Self-Report;Play;Policies;Policy Maker;Policy Making;population health;prevent;Prevention;Process;Quasi-experiment;Race;racial difference;racial discrimination;racial disparity;racial diversity;racism;Records;Research;Resources;Risk;Role;Sampling;Shapes;Stress;System;Time;Variant;Vital Statistics;Wages;Work

PROJECT_TITLE: Examining the Impact of Pandemic Eviction Prevention Policies on Racial Inequalities in Mortality


ADMINISTERING_IC: VA

IC_NAME: Veterans Affairs

ORG_NAME: VETERANS HEALTH ADMINISTRATION

PHR: PROJECT NARRATIVE Allergic diseases are a major burden to public health in the United States. This is of particular relevance to Veterans of the U.S. Military in whom the prevalence of allergic rhinitis is approximately 30% and allergic asthma is approximately 3%. Thus, allergic diseases are an important cause of morbidity among Veterans. Our preliminary data reveals that prostaglandin (PG) I2 lymphocytes. PGI2 inhibi glycolysis and pathway analysis strongly suggests that this occurs by PGI2 signali ng critically regulates the metabolic program of CD4 Th2 restraining glutamine and glutamate metabolism. This is supported by our in vivo data that reveals that PGI2 signaling inhibits pro-inflammatory metabolic pathways and that this is the mechanism by which it restrains allergic inflammation in the lung. Our studies have important therapeutic implications as PGI2 and PGI2 analogs are approved by the Food and Drug Administration (FDA) for treatment of pulmonary hypertension, and therefore their use could be extended for the treatment of allergic airway diseases such as asthma. ted

PI_NAMEs: PEEBLES, RAY STOKES (contact)

PROJECT_TERMS: airway inflammation;Allergens;allergic airway disease;allergic airway inflammation;Allergic Disease;Allergic inflammation;Allergic rhinitis;Alternaria;Amino Acids;analog;Animals;Antiinflammatory Effect;Arachidonic Acids;Asthma;Award;Basic Science;CD4 Positive T Lymphocytes;Cell Separation;Cells;Cellular Metabolic Process;Chronic Disease;clinically relevant;CRISPR screen;cytokine;Data;Development;Disease;Disease Pathway;Effector Cell;Energy-Generating Resources;Enzymes;Eosinophilia;Epoprostenol;experimental study;Extrinsic asthma;fluorodeoxyglucose positron emission tomography;Funding;Genetic;Glucose;Glucose Transporter;glucose uptake;Glutamate Metabolism Pathway;Glutamates;Glutaminase;Glutamine;Glycolysis;Glycolysis Inhibition;Health;Human;Human Biology;human disease;Hypersensitivity;In Vitro;in vivo;in vivo Model;Inflammatory;Interleukin-13;Interleukin-5;Link;LoxP-flanked allele;Lung;Lymphocyte;Metabolic;Metabolic Pathway;Metabolism;metabolomics;Military Personnel;model organism;Morbidity - disease rate;Mucous body substance;Mus;novel;novel therapeutics;Nutrient;Pathogenicity;Pathway Analysis;Pathway interactions;Pharmaceutical Preparations;pharmacologic;Positron-Emission Tomography;Prevalence;Principal Investigator;programs;Prostaglandin-Endoperoxide Synthase;Prostaglandins;Public Health;Publishing;Pulmonary Hypertension;receptor;Regulation;Reporter;Resources;restraint;Role;Signal Transduction;Testing;Therapeutic;translational study;United States;United States Food and Drug Administration;uptake;Veterans

PROJECT_TITLE: PGI2 regulation of CD4+ Th2 metabolism in allergic airway inflammation


NIH_SPENDING_CATS: Behavioral and Social Science;Brain Disorders;Clinical Research;Clinical Trials and Supportive Activities;Eating Disorders;Mental Health;Mental Illness;Nutrition;Pediatric;Serious Mental Illness

ORG_CITY: STANFORD

ORG_DEPT: PSYCHIATRY

ORG_NAME: STANFORD UNIVERSITY

PHR: This application proposes examining the efficacy and mechanism of family therapy compared to usual care for children between the ages of 6 and 12 who are diagnosed with Avoidant restrictive food intake disorder. Preliminary data suggests that family therapy is superior to usual care and that improvement in parental self-efficacy related to feeding their children is the mechanism of treatment. In addition, this study will attempt to identify specific patient groups who respond to family therapy.

PI_NAMEs: LOCK, JAMES D (contact)

PROGRAM_OFFICER_NAME: BURSTEIN, MARCY ELLEN

PROJECT_TERMS: 12 year old;Academy;Address;Adolescent;adverse outcome;Affect;Aftercare;Age;Ambulatory Care;American;Anorexia Nervosa;Attention;avoidant restrictive food intake disorder;Behavior;Blinded;Body Image;Body Weight;Bulimia;Caring;Child;Child Abuse;Child Care;child neglect;Child Rearing;Choking;Cognition;Color;Data;Developmental Delay Disorders;Diagnosis;Diagnostic and Statistical Manual of Mental Disorders;DSM-V;Eating;Eating Behavior;Eating Disorders;Education;effective therapy;efficacy evaluation;Evidence based treatment;Exclusion;Family;Family psychotherapy;family structure;Family Study;Feasibility Studies;feeding;Feeding behaviors;follow-up;Fright;Growth;improved;Intelligence;interest;Intervention Studies;Interview;Maintenance;Malnutrition;Manuals;Mediator;Medical;Mental disorders;Mental Health;Monitor;Nonpharmacologic Therapy;Outcome;Parents;Participant;Patients;Pediatrics;Pica Disease;Prevalence;primary outcome;psychiatric comorbidity;psychosocial;Psychotic Disorders;Questionnaires;Randomized;Recording of previous events;recruit;response;rho;Rumination Disorders;secondary outcome;Self Efficacy;Sensory;severe mental illness;Severities;Signal Transduction;social;Tail;Taste Perception;Texture;Time;treatment as usual;treatment duration;treatment effect;Treatment outcome;Validation;Vomiting;Weight;Weight Gain;Writing;Youth

PROJECT_TITLE: Confirming the Efficacy/Mechanism of Family Therapy for Children with Low Weight Avoidant/Restrictive Food Intake Disorder (ARFID)


NIH_SPENDING_CATS: Biodefense and Related Countermeasures;Clinical Research;Clinical Trials and Supportive Activities;Emerging Infectious Diseases;Hematology;Infectious Diseases;Lung;Orphan Drug;Rare Diseases;Sepsis;Tuberculosis

ORG_CITY: CHARLOTTESVILLE

ORG_NAME: UNIVERSITY OF VIRGINIA

ORG_STATE: VA

PHR: PROJECT NARRATIVE Sepsis is a syndrome of critical illness defined as life-threatening organ dysfunction due to a dysregulated host response to infection and is a leading cause of global mortality. In sub-Saharan Africa, tuberculosis (TB) is a common driver of sepsis in people living with HIV and is associated with high mortality rates. Yet TB sepsis is difficult to identify clinically and microbiologically, so many patients with TB sepsis go untreated, or have delays in treatment. Therefore, we propose a randomized 2x2 factorial clinical trial to compare 28 day survival from sepsis between study participants who receive 1) empiric immediate initiation of anti-TB therapy plus standard care or diagnosis dependent anti-TB therapy plus standard care and 2) sepsis-specific dose anti-TB therapy plus standard care or conventional dose anti-TB therapy plus standard care. This clinical trial will deliver important knowledge about the optimal content, dosing, and timing of the antimicrobial regimen for adult sepsis in sub-Saharan Africa.

PI_NAMEs: HEYSELL, SCOTT K (contact);MOORE, CHRISTOPHER CHARLES

PROGRAM_OFFICER_NAME: LAUGHON, BARBARA E

PROJECT_TERMS: Achievement;Admission activity;Adult;Adverse drug event;Africa;Africa South of the Sahara;Antibiotic Therapy;antimicrobial;Antitubercular Agents;Area;Blood;Cessation of life;Clinical;clinical trial participant;Clinical Trials;community advisory board;conventional dosing;Critical Illness;Death Rate;design;Diagnosis;Diagnostic tests;Dose;Drug Kinetics;early phase clinical trial;Early treatment;Etiology;Functional disorder;global health;Goals;Health Priorities;HIV;HIV-2;HIV/TB;Hospital Mortality;Hospitalization;Immune response;improved;Infection;isoniazid;Karnofsky Performance Status;Knowledge;Life;lipoarabinomannan;Measures;microbial;mortality;Mycobacterium tuberculosis;Odds Ratio;open label;Organ;Participant;Patients;Persons;Pharmaceutical Preparations;Pharmacodynamics;Phase;point-of-care diagnostics;Polymerase Chain Reaction;primary endpoint;prospective;Randomized;randomized, clinical trials;Recommendation;Regimen;Rifampin;Risk Reduction;Sample Size;secondary endpoint;Sepsis;septic patients;Serum;Side;Site;Sputum;standard care;standard of care;Syndrome;Tanzania;Temperature;Testing;Time;Tuberculosis;Tuberculosis diagnosis;tuberculosis drugs;tuberculosis treatment;Uganda;Undifferentiated;urinary;Vulnerable Populations;Weight;World Health Organization

PROJECT_TITLE: A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa


NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Brain Disorders;Clinical Research;Clinical Trials and Supportive Activities;Dementia;Genetics;Neurodegenerative;Neurosciences

ORG_CITY: Framingham

ORG_NAME: ALZHEON, INC.

PHR: Project Narrative There are currently no disease-modifying treatments that can halt or slow the progressive cognitive decline of Alzheimer’s disease (AD). We are developing a new, oral medication, ALZ-801, that inhibits soluble toxic amyloid oligomers, the upstream drivers of neurodegeneration. We intend to conduct a Phase 3 clinical trial in AD patients who carry two copies of the high-risk, apolipoprotein E4 gene, to test if the drug can improve cognition, reduce brain atrophy, and have positive effects on CSF and plasma biomarkers of neurodegeneration in AD. If successful, we will seek FDA approval so that APOE4/4 AD patients can benefit from this therapy.

PI_NAMEs: ABUSHAKRA, SUSAN  (contact)

PROGRAM_OFFICER_NAME: RYAN, LAURIE M

PROJECT_TERMS: abeta oligomer;Aducanumab;Adverse event;Alleles;Alzheimer's Disease;Alzheimer's disease patient;Alzheimer's disease risk;Alzheimer’s disease biomarker;Amyloid;Amyloid beta-Protein;Antibodies;Apolipoprotein E;apolipoprotein E-4;Atrophic;Automobile Driving;beta-site APP cleaving enzyme 1;Biological Availability;Biological Markers;Blood Vessels;Brain;cerebral atrophy;Characteristics;Clinical;Clinical Data;clinical efficacy;Clinical Investigator;Clinical Research;Clinical Trials;Cognition;Cognitive;Data;Data Set;Delayed Memory;Dementia;Disease;Disease Outcome;disease phenotype;Dose;Double-Blind Method;Drug Approval;drug candidate;Drug Kinetics;drug testing;efficacy evaluation;efficacy outcomes;Elderly;Enrollment;experience;Formulation;functional outcomes;Future;gastrointestinal;Genes;Genotype;Goals;high risk;Hippocampus;Homozygote;Image;imaging biomarker;Impaired cognition;improved;Incidence;indexing;inhibitor;insight;Light;Magnetic Resonance Imaging;Medical Economics;Memory;mental state;Microglia;Modification;monomer;Nausea and Vomiting;Nerve Degeneration;neurofilament;neurogranin;neuropsychiatric symptom;Oral;Outcome;participant enrollment;Pathology;Patients;Pharmaceutical Preparations;Phase;phase 1 study;phase 2 study;phase 3 study;Phase III Clinical Trials;phase III trial;Placebo Control;Placebos;Plasma;Population;Positron-Emission Tomography;pre-clinical;Prodrugs;Production;Property;Protocols documentation;Quality of life;Randomized;Risk;Role;Safety;Sample Size;Signal Transduction;small molecule;socioeconomics;Specific qualifier value;study population;Sum;Synapses;Tablets;tau Proteins;tau-1;Testing;trial design;vasogenic edema;β-amyloid burden

PROJECT_TITLE: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study


NIH_SPENDING_CATS: Biotechnology;Chronic Obstructive Pulmonary Disease;Clinical Research;Genetics;HIV/AIDS;Human Genome;Lung;Tobacco;Tobacco Smoke and Health

ORG_CITY: BROOKLYN

ORG_NAME: SUNY DOWNSTATE MEDICAL CENTER

PHR: Principal Investigator/Program Director (Last, First, Middle): Foronjy, Robert Francis HIV infection accelerates the development of chronic obstructive pulmonary disease (COPD), which is a leading cause of morbidity and mortality in people living with HIV. The RNA binding protein Human Antigen R (HuR) regulates global expression and supports the production of key repair mediators in the airway epithelium. This proposal will advance public health by determining how cigarette smoke and HIV virus promote airflow obstruction and airway remodeling in HIV by repressing HuR to alter the airway epithelial transcriptome. PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Page Continuation Format Page

PI_NAMEs: FORONJY, ROBERT F (contact)

PROGRAM_OFFICER_NAME: PUNTURIERI, ANTONELLO

PROJECT_TERMS: Acceleration;adeno-associated viral vector;Air Movements;Airway Disease;airway epithelium;airway obstruction;airway remodeling;Antigens;Antioxidants;Binding;Biological Assay;Biology;Cell Differentiation process;Cell Nucleus;Cell Proliferation;Cell Separation;cell type;Cells;Cellular biology;Chronic;Chronic Obstructive Pulmonary Disease;cigarette smoke;cigarette smoke-induced COPD;Cilia;Code;cohort;Cohort Analysis;Collecting Cell;Complex;Computer software;Cysteine;Cytosol;Data;Development;Disease;disease model;drinking water;early onset;Epithelial Cells;epithelial injury;epithelial repair;Equilibrium;exposure to cigarette smoke;Female;Functional disorder;Gene Expression;Gene Expression Profile;Gene Expression Profiling;Genes;HIV;HIV Envelope Protein gp120;HIV Infections;HIV tat Protein;Human;human disease;Image;Impairment;improved;In Vitro;in vivo;Individual;Inhalation;injured airway;Injury;Intervention;knock-down;knockout gene;Knockout Mice;Left;Longevity;Longitudinal cohort;Lung;male;Measures;Mediating;Mediator;Messenger RNA;MicroRNAs;Modeling;Molecular;Morbidity - disease rate;mortality;mouse model;mRNA Decay;mRNA Export;Mus;nef Protein;novel;Outcome;oxidative damage;Pathway interactions;patient population;Persons;pharmacologic;Physiological;premature;prevent;Principal Investigator;Production;programs;protein-tyrosine kinase c-src;Proteins;Proto-Oncogenes;Public Health;pulmonary function;Random Allocation;repaired;Repression;respiratory imaging;response;Retrospective cohort;Risk Factors;RNA;RNA-Binding Proteins;Role;single cell sequencing;Smoke;SRC gene;Stains;Structure of parenchyma of lung;Testing;Trachea;trafficking;transcriptome;transcriptome sequencing;transcriptomic profiling;transcriptomics;Translations;Viral;Virus

PROJECT_TITLE: The Role of HuR in HIV related COPD

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-IDIB-B(02)]


ED_INST_TYPE: SCHOOLS OF PUBLIC HEALTH

ORG_CITY: BOSTON

ORG_DEPT: BIOSTATISTICS & OTHER MATH SCI

ORG_NAME: BOSTON UNIVERSITY MEDICAL CAMPUS

PHR: PROJECT NARRATIVE Biostatistics plays a fundamental role in biomedical and public health research. This program trains predoctoral Biostatistics students to become effective collaborators in a wide range of biomedical disciplines, with a strong emphasis on research ethics and reproducible science. Trainees also receive enhanced career and professional development training to prepare them to contribute to the improvement of public health.

PI_NAMEs: LUNETTA, KATHRYN L;WHITE, LAURA FORSBERG (contact)

PROGRAM_OFFICER_NAME: STAMM, JOYCE CHIN-CHIN NG

PROJECT_TERMS: Training Programs

PROJECT_TITLE: BUSPH Interdisciplinary Training Program for Biostatisticians

STUDY_SECTION: TWD

STUDY_SECTION_NAME: Training and Workforce Development Study Section - B[TWD-B]


NIH_SPENDING_CATS: Behavioral and Social Science;Breast Cancer;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Nutrition;Obesity;Prevention;Rehabilitation;Sleep Research;Women's Health Research

ORG_CITY: BALTIMORE

ORG_NAME: JOHNS HOPKINS UNIVERSITY

ORG_STATE: MD

PHR: Narrative: Overweight/obesity and sleep problems, including insomnia disorder, increase women’s risk of breast cancer and poor treatment outcomes. Behavioral weight loss and sleep interventions are effective for many patients; however, they have never been combined and examined in a large clinical trial to see if they result in better weight loss. We plan to combine cognitive behavioral treatment for insomnia with behavioral weight loss, delivered using video technology, to determine if treating insomnia prior to weight loss in breast cancer survivors is associated with better weight loss, sleep, dietary and physical activity changes compared to no sleep intervention.

PI_NAMEs: SMITH, MICHAEL T;WILDER COUGHLIN, JANELLE  (contact)

PROGRAM_OFFICER_NAME: HALL, KARA L

PROJECT_TERMS: Address;Adult women;Behavior;Behavioral;Biological;Body Composition;Body fat;Body Weight;Body Weight decreased;breast cancer diagnosis;Breast Cancer Risk Factor;breast cancer survival;Breast Cancer survivor;Breast Cancer survivorship;Breast Cancer Treatment;Caloric Restriction;Calories;cancer recurrence;Cancer Relapse;cancer survival;cancer therapy;Cessation of life;Chronic Insomnia;Clinical;Clinical Trials;clinically significant;Cognitive Therapy;comorbidity;comparison intervention;Complex;Consumption;Data;Diet;dietary;disorder risk;Education;effective intervention;Energy Intake;evidence base;Fatty acid glycerol esters;Food;General Population;Healthcare;Impairment;improved;improvement on sleep;Incidence;Individual;innovation;International Agency for Research on Cancer;Intervention;Knowledge;Link;Long Term Survivorship;Malignant Breast Neoplasm;Malignant Neoplasms;Mediating;Medical;Metabolic syndrome;Morbidity - disease rate;mortality;multidisciplinary;novel;novel strategies;Obesity;obesity treatment;Outcome;Outcome Measure;Overweight;Participant;Pathway interactions;Patients;Physical activity;poor sleep;Practice Guidelines;Prevalence;prevent;prospective;Randomized;Randomized Controlled Clinical Trials;Recommendation;Recording of previous events;Recurrence;Research;Risk;Sleep;Sleep Deprivation;Sleep Disorders;Sleep disturbances;sleep quality;Sleeplessness;standard care;Survivors;Technology;telehealth;Testing;Time;translational clinical trial;Treatment Efficacy;treatment group;treatment guidelines;Treatment outcome;United States;Weight;Weight Gain;weight loss intervention;weight maintenance;Woman;women's outcomes

PROJECT_TITLE: The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer

STUDY_SECTION: LCBH

STUDY_SECTION_NAME: Lifestyle Change and Behavioral Health Study Section[LCBH]


ORG_NAME: UNIVERSITY OF MARYLAND BALTIMORE

PHR: Lay Description of Work: Future advancements in our ability to fight infection, inflammatory diseases like arthritis, and cancer depends on advanced training of scientists in the relatively new field of “innate immunity.” Our Training Program, Signaling Pathways in Innate Immunity (SPII), provides predoctoral and postdoctoral trainees with the the analytical skills required to “connect the dots” and unravel complex molecular interactions that underlie our earliest immune responses to microbes and other noxious substances. Towards this goal, talented SPII trainees receive exceptional multidisciplinary academic support, research guidance, and mentoring from our dedicated faculty, as evidenced by the scientific successes of SPII trainees in its first ten years.

PI_NAMEs: VOGEL, STEFANIE N. (contact)

PROGRAM_OFFICER_NAME: GONDRE-LEWIS, TIMOTHY A

PROJECT_TERMS: Natural Immunity;Signal Pathway

PROJECT_TITLE: Signaling Pathways in Innate Immunity

STUDY_SECTION: AITC

STUDY_SECTION_NAME: Allergy, Immunology, and Transplantation Research Committee[AITC]


NIH_SPENDING_CATS: Biotechnology;Clinical Research;Genetics;Human Genome;Infectious Diseases;Patient Safety;Prevention

ORG_CITY: DURHAM

ORG_NAME: DUKE UNIVERSITY

ORG_STATE: NC

PHR: Project Narrative Nontuberculous mycobacterial (NTM) infections cause substantial morbidity and mortality, and rates of NTM infections acquired at healthcare facilities are increasing. The proposed studies will develop an advanced statistical strategy for NTM surveillance within a hospital network and utilize molecular sequencing of NTM isolates to improve understanding of healthcare facility NTM acquisition. This work will determine if the combination of advanced statistical surveillance and molecular sequencing can improve NTM surveillance and understanding of NTM acquisition, ultimately preventing NTM infections and reducing risk of harm to hospitalized patients.

PI_NAMEs: BAKER, ARTHUR W (contact)

PROGRAM_OFFICER_NAME: MENDEZ, SUSANA

PROJECT_TERMS: Affect;Biological;Clinical;clinical sequencing;Clostridium difficile;compare effectiveness;Complement;Coupled;Data;Dedications;design;Detection;Development;Disease Outbreaks;Early Diagnosis;Effectiveness;emerging pathogen;Environment;Environmental Pollution;Epidemiologic Methods;Exhibits;experience;follow-up;genome sequencing;Genomics;Goals;Health care facility;Health Care Rationing;Healthcare;healthcare-associated infections;Heart Transplantation;Hospitalization;Hospitals;Immunocompromised Host;improved;Incidence;Infection;Infection Control;infection risk;innovation;Institution;Intervention;Investigation;Lung Transplantation;Mentors;Methods;Molecular;Molecular Epidemiology;Morbidity - disease rate;mortality;Mycobacterium Infections;non-tuberculosis mycobacteria;non-tuberculous mycobacterial infection;novel;novel strategies;outbreak control;Outcome;Patients;Phylogenetic Analysis;Physicians;Population;prevent;prevent outbreaks;Prevention;Process;prospective;Randomized, Controlled Trials;Research;Risk Reduction;Scientist;skills;Source;Statistical Computing;Surgical Wound Infection;Surveillance Methods;Techniques;Testing;Time Series Analysis;Training;Transplant Recipients;Transplantation;Variant;Vulnerable Populations;whole genome;Work

PROJECT_TITLE: Combined Use of Statistical Process Control and Whole Genome Sequencing to Detect and Investigate Nontuberculous Mycobacterial Clusters and Outbreaks

STUDY_SECTION: MID

STUDY_SECTION_NAME: Microbiology and Infectious Diseases B Research Study Section[MID-B]


NIH_SPENDING_CATS: Acute Respiratory Distress Syndrome;Coronaviruses;Coronaviruses Therapeutics and Interventions;Emerging Infectious Diseases;Infectious Diseases;Lung;Pneumonia;Pneumonia and Influenza;Rare Diseases

ORG_CITY: IRVINE

ORG_NAME: UNIVERSITY OF CALIFORNIA-IRVINE

ORG_STATE: CA

PHR: NARRATIVE (General Audience, public health relevance, 2-3 sentences) This research addresses a specific unmet medical need, the absence of an effective medical therapy for acute lung injury (ALI), a common disorder in patients with bacterial pneumonia or SARS-CoV-2 infec- tion and its severe form, acute respiratory distress syndrome (ARDS) that is fatal in 40% of patients. The work is broadly impactful because the white blood cells called neutrophils (Polymorphonuclear leuko- cytes, PMN) that damage the lungs in infectious ALI/ARDS also cause other acute and chronic inflam- matory diseases. In the last period, we showed that the human voltage-gated proton channel (hHv1) in PMN is essential to produce the inflammatory response, and we propose here to confront lung injury by a novel strategy: targeting hHv1 in PMN, both directly and by blocking a natural activator of hHv1, al- bumin (Alb), that we recently reported to be required for hHv1 operation, thereby offering two ways to confront the disease at the earliest stage before it becomes a more complex disorder.

PI_NAMEs: GOLDSTEIN, STEVE A N (contact);ZHAO, RUIMING

PROGRAM_OFFICER_NAME: ZHOU, GUOFEI

PROJECT_TERMS: Acrosome Reaction;Acute;Acute Lung Injury;Acute Respiratory Distress Syndrome;Address;Affinity;Air;Albumins;Anti-Inflammatory Agents;Automobile Driving;Bacteria;Bacterial Pneumonia;base;Binding;Biophysics;Bronchoalveolar Lavage Fluid;Cells;Cessation of life;Chronic;chronic inflammatory disease;combat;Complex;COVID-19;COVID-19 pandemic;cytokine;Data;design;Development;Disease;Effectiveness;Elastases;experience;extracellular;Fertilization;Fluorescence Resonance Energy Transfer;Functional disorder;fungus;Generations;Goals;Grant;Health;Hospitalization;Host Defense;Human;Hypoxemia;Immune;Immunologic Stimulation;improved;In Vitro;in vivo;Infection;Inflammation;Inflammation Mediators;Inflammatory;Inflammatory Response;inhibitor;Innate Immune System;innovation;Ischemic Stroke;Knock-out;Knockout Mice;Leukocytes;Life;Ligands;Liquid substance;Lung;Lung Compliance;lung injury;Mediating;Medical;Membrane;Methods;Microscopy;Modeling;Morbidity - disease rate;mortality;mouse model;Mus;neutrophil;novel;novel strategies;Oocytes;operation;Oxidants;Oxidases;Pathology;Pathway interactions;Patients;Peptide Hydrolases;Peptides;Phagocytes;Pharmaceutical Preparations;pharmacologic;Pharmacology;Pharmacology Study;Pharmacotherapy;Physiology;Pneumonia;Production;Proteins;Protons;Public Health;public health relevance;Publishing;rational design;Reactive Oxygen Species;Regulation;Reporting;Research;Respiratory Burst;response;Role;SARS-CoV-2 infection;Sepsis;single molecule;Site;Speed;Sperm Capacitation;sperm cell;structural biology;Structure;success;tool;Variant;Virus;voltage;Wild Type Mouse;Work

PROJECT_TITLE: hHv1 channels in neutrophils and the innate immune inflammatory response

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-BCMB-G(02)]


NIH_SPENDING_CATS: Brain Cancer;Brain Disorders;Cancer;Neurosciences;Nutrition;Rare Diseases

ORG_CITY: Columbus

ORG_DEPT: RADIATION-DIAGNOSTIC/ONCOLOGY

ORG_NAME: OHIO STATE UNIVERSITY

ORG_STATE: OH

PHR: PROJECT NARRATIVE Glioblastoma (GBM) is the most common primary brain tumor in adults and one of the most deadly cancers, with a median survival of only 12-15 months despite extensive treatment. This application aims to identify the important new role of clinically-relevant retinoic acids in regulating lipid metabolism and to unveil the underlying resistance mechanism of GBM to this therapy. Completion of this study will provide a new and very promising combination strategy to treat GBM by concurrently inhibiting lipid synthesis and oxidation using clinically available drugs, thereby building the foundation for further testing in GBM patients.

PI_NAMEs: GUO, DELIANG  (contact)

PROGRAM_OFFICER_NAME: WILLIS, KRISTINE AMALEE

PROJECT_TERMS: Acute Promyelocytic Leukemia;Adult;Binding;Biology;Brain Neoplasms;cancer cell;Carnitine Palmitoyltransferase I;Cell Death;Cell Survival;Cells;Ceramides;Cholesterol;Clinical;Clinical Research;clinically relevant;cohort;Combined Modality Therapy;Data;Dose;Down-Regulation;efficacy evaluation;endoplasmic reticulum stress;Energy Metabolism;Enzymes;fatty acid oxidation;Fatty Acids;Foundations;Gene Expression;Gene Mutation;gene synthesis;Genes;Genus Hippocampus;Glioblastoma;Glycolysis;Goals;Growth;Homeostasis;improved;In Vitro;in vivo;insight;Isotretinoin;Laboratories;lipid biosynthesis;lipid metabolism;lipidomics;Lipids;Malignant Neoplasms;Measures;Mediating;metabolomics;Mitochondria;Molecular;neoplastic cell;novel;novel strategies;Nuclear Receptors;Outcome;oxidation;Patients;Pharmaceutical Preparations;pharmacologic;Phospholipids;Play;Primary Brain Neoplasms;Production;Prognosis;rapid growth;Regulation;Reporting;Resistance;Resistance development;resistance mechanism;response;Role;Sampling;screening;Solid Neoplasm;SRE-1 binding protein;synergism;Testing;Tissues;transcription factor;Tretinoin;tumor;tumor growth;Tumor Promotion;Tumor Tissue;uptake

PROJECT_TITLE: Delineating how retinoic acids regulate lipid metabolism in glioblastoma and their resistance mechanisms

STUDY_SECTION_NAME: Mechanisms of Cancer Therapeutics - 1 Study Section[MCT1]


NIH_SPENDING_CATS: Aging;Clinical Research;Social Determinants of Health

ORG_CITY: NEW YORK

ORG_NAME: NEW YORK UNIVERSITY SCHOOL OF MEDICINE

PHR: NARRATIVE Interprofessional collaboration and workforce diversity are known to be important to care quality for older adults, but have not been well studied within aging research practice. This proposal investigates how to maximize diversity and interprofessional collaboration in aging research and will provide greater understanding of the aging research community’s needs and produce actionable insights to diversify and strengthen collaborations created. By providing experience in aging research, social network analysis, intervention development, and organizational behavior, the research plan is highly complementary to the career development of an independent aging researcher focused on developing interventions to promote interprofessional collaboration and improve the quality of aging research and care.

PI_NAMEs: STEVENS, ELIZABETH REID (contact)

PROGRAM_OFFICER_NAME: BAKOS, ALEXIS DIANE

PROJECT_TITLE: Advancing the Development of Collaborative Research Networks to Enhance Aging Research Value

STUDY_SECTION: AGCD

STUDY_SECTION_NAME: Career Development For Early Career Investigators Study Section [AGCD-2]


NIH_SPENDING_CATS: Biotechnology;Cancer;Childhood Leukemia;Hematology;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

ORG_NAME: THOMAS JEFFERSON UNIVERSITY

PHR: Project Narrative Ph+ and Ph1-like acute lymphoblastic leukemia (ALL) cells rely on the expression of the cell cycle regulatory protein CDK6 for their proliferation and survival. The effects of CDK6 are, in part, kinase-independent. This proposal focuses on assessing the role of CDK6 through genetic and pharmacological interventions based on CDK4/6-targeted PROTACs that inhibit the enzymatic activity of CDK6 and promote its degradation.

PI_NAMEs: CALABRETTA, BRUNO  (contact);SALVINO, JOSEPH M

PROGRAM_OFFICER_NAME: KLAUZINSKA, MALGORZATA

PROJECT_TERMS: Acute;acute lymphoblastic leukemia cell;Acute Lymphocytic Leukemia;Adult;advanced breast cancer;B-Cell Acute Lymphoblastic Leukemia;Biological;Blood;Cancer Biology;cancer therapy;Catalytic Domain;CDK4 gene;Cell Cycle;Cell Cycle Proteins;cell growth;Cell Line;Clinic;Clinical;Combination Drug Therapy;Complex;Cyclin D1;cyclin-dependent kinase 6;Cyclin-Dependent Kinase Inhibitor 2A;Cytoplasm;Development;Dose;Down-Regulation;Drug Kinetics;effective therapy;Exhibits;FDA approved;Gene Expression;Gene Expression Profile;Gene Expression Regulation;Generations;Genes;Genetic;Genetic Transcription;Goals;Growth;Half-Life;HDAC1 gene;Hematologic Neoplasms;high risk;high throughput screening;Human;Imatinib;improved;improved outcome;In Vitro;in vitro activity;in vivo;inhibitor;innovation;Intervention;intraperitoneal;Knowledge;Laboratories;Lead;leukemia;leukemia treatment;Link;Liver Microsomes;Malignant Neoplasms;Metabolic;Metabolic Pathway;Mitochondria;MLL-rearranged leukemia;Molecular;mouse model;Mus;Mutation;novel;novel therapeutics;Nuclear;Oral;Outcome;patient derived xenograft model;Patients;Pharmaceutical Chemistry;pharmacologic;Philadelphia;Phosphotransferases;Plasma;pre-clinical;Prognosis;Proliferating;Property;Protac;prototype;Recurrent disease;Relapse;Resistance;Resistance development;Role;Route;S phase;Specificity;Structure-Activity Relationship;Subgroup;Testing;Therapeutic Agents;Therapeutic Effect;therapeutically effective;Tyrosine Kinase Inhibitor;validation studies

PROJECT_TITLE: Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL)

STUDY_SECTION_NAME: Mechanisms of Cancer Therapeutics - 2 Study Section[MCT2]


NIH_SPENDING_CATS: Antimicrobial Resistance;Biotechnology;Genetics;Infectious Diseases;Malaria;Orphan Drug;Rare Diseases;Vector-Borne Diseases

ORG_CITY: TAMPA

ORG_DEPT: OTHER HEALTH PROFESSIONS

ORG_NAME: UNIVERSITY OF SOUTH FLORIDA

PHR: Narrative Malaria remains a devastating global health problem, although tremendous progress has been achieved in the past decade. Much of the progress can be attributed to effective use of drug treatments for Plasmodium falciparum, especially artemisinin (ART) combination therapies (ACTs); however, emerging resistance to ART (ART-R) and the ACT partner drugs threatens this progress. Our experimental approach is to elucidate drug-gene associations and decipher mechanisms of action and resistance to ART and other antimalarial drugs, using forward genetic screens of P. falciparum mutants created by random piggyBac mutagenesis.

PI_NAMEs: ADAMS, JOHN H (contact)

PROGRAM_OFFICER_NAME: JOY, DEIRDRE A

PROJECT_TERMS: Africa;Anabolism;Anti-malarial drug resistance;Anti-malarials;Artemisinins;artesunate;asexual;Asia;biological adaptation to stress;Blood;Cessation of life;Circulation;Clinical;Combined Modality Therapy;comparative;Complex;coping;cost;Coupled;CRISPR/Cas technology;Development;Digestion;Disease;DNA Sequence Alteration;drug discovery;Drug Targeting;Drug usage;Falciparum Malaria;Fever;fitness;Food;gene conservation;gene discovery;Gene Expression Profile;Genes;Genetic Crosses;Genetic Screening;Genome;genome editing;Genomic Library;genomic profiling;Genomics;Genotype;global health;Heat-Shock Response;Heme;Hemoglobin;Human;inhibitor;isoprenoid;Libraries;Link;Malaria;Measures;Mediating;Metabolic;Modeling;multicatalytic endopeptidase complex;Mutagenesis;mutant;Mutation;Ontology;Oxidative Stress;Parasites;Pathway interactions;Pharmaceutical Preparations;Pharmacotherapy;Phenotype;Plasmodium;Plasmodium falciparum;Plasmodium vivax;Process;Proteins;Reactive Oxygen Species;Research;Resistance;response;tool;Toxic effect;transcriptome sequencing;Vacuole;Volatilization;whole genome

PROJECT_TITLE: Chemogenomic Profiling of Plasmodium Falciparum Responses and Resistance

STUDY_SECTION: DDR

STUDY_SECTION_NAME: Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section[DDR]


NIH_SPENDING_CATS: Biodefense and Related Countermeasures;Biotechnology;Emerging Infectious Diseases;Hematology;Infectious Diseases;Lung;Prevention;Rare Diseases

ORG_CITY: TORRANCE

ORG_NAME: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER

PHR: PROJECT NARRATIVE Current treatment options for mucormycosis (commonly caused by Rhizopus delemar) are inadequate, and fail in 40% or more of infected patients. The fungus uses proteins and toxic substances to invade host cell tissues and cause disease. We propose to identify methods by which these proteins and toxic substances invade and kill host cells, so we can design better and more efficient therapeutic strategies to prevent or treat these lethal infections.

PI_NAMEs: IBRAHIM, ASHRAF S. (contact)

PROGRAM_OFFICER_NAME: LOVE, DONA

PROJECT_TERMS: Adherens Junction;ADP-ribosylation factor 6;Adrenal Cortex Hormones;alveolar epithelium;Angioinvasion;anti-fungal agents;Antibodies;Antifungal Therapy;Apoptosis;base;Binding;Biochemical;Blocking Antibodies;Blood Vessels;Brain;Cell Death;Cell Line;Cell surface;Cells;Cessation of life;Clinical;clinically relevant;Cross Reactions;cross reactivity;Data;Death Rate;design;diabetic;Diabetic Ketoacidosis;Disease;Edema;efficacy evaluation;Endothelial Cells;Endothelium;Epidermal Growth Factor Receptor;Epithelial Cells;Epithelium;Epitope Mapping;Event;Extracellular Matrix;FDA approved;Funding;fungus;Galactose Binding Lectin;Galectin 1;Genes;genetic approach;Germination;glucose-regulated proteins;GRP78 gene;Hematogenous;Hematopoietic;Human;Hyphae;Immunocompetent;Immunocompromised Host;In Vitro;in vivo;Incidence;Induction of Apoptosis;Infection;Inhalation;inhibiting antibody;inhibitor;Integrin alpha3beta1;Integrins;Invaded;Iron;Knockout Mice;Life;Lung Diseases;Methods;Molecular;Monoclonal Antibodies;monolayer;Monomeric GTP-Binding Proteins;mortality;mouse model;Mucorales;Mucormycosis;Mus;Mutation;Mycotoxins;Names;nanobodies;Nasal Epithelium;Necrosis;necrotic tissue;Neutropenia;new therapeutic target;novel;novel therapeutic intervention;Operative Surgical Procedures;Orbital Diseases;Organ;Organ failure;Organ Transplantation;Pathogenesis;Pathway interactions;Patients;Penetration;Pericytes;Pharmaceutical Preparations;Plants;Play;Poison;preclinical development;Prevalence;prevent;Prevention strategy;Process;Production;Progress Reports;Proteins;receptor;Receptor Cell;Reproduction spores;Rhizopus;Ribosomes;Ricin;Ricin B Chain;Risk Factors;Role;Seminal;Sequence Homologs;Serum;Small Interfering RNA;Solid;Therapeutic;Thrombosis;Tissues;Toxin;TP53 gene;Treatment Failure;treatment strategy;Tumor Suppressor Proteins;Umbilical vein;Vascular Permeabilities;virtual;Virulence;wound

PROJECT_TITLE: Novel Toxins and Receptors in Mucormycosis Pathogenesis and Treatment


ADMINISTERING_IC: DA

IC_NAME: NATIONAL INSTITUTE ON DRUG ABUSE

NIH_SPENDING_CATS: Biotechnology;Brain Disorders;Drug Abuse (NIDA only);Genetics;HIV/AIDS;Infectious Diseases;Methamphetamine;Neurodegenerative;Neurosciences;Stem Cell Research;Stem Cell Research - Induced Pluripotent Stem Cell;Stem Cell Research - Induced Pluripotent Stem Cell - Human;Stimulant Use and Misuse;Substance Misuse

ORG_CITY: PHILADELPHIA

ORG_NAME: DREXEL UNIVERSITY

PHR: An increasing number of people living with HIV use stimulants, such as Methamphetamine and Cocaine, but the cellular and molecular mechanisms by which stimulants interact with HIV and anti-retroviral therapy (ART) to drive neuroinflammation and promote neuronal dysfunction and neurocognitive impairment are poorly understood. We propose to resolve this knowledge gap by creating a consistent, translationally relevant, human cell-culture model of microglia and dopamine neurons that can release dopamine, enabling precise evaluation of the effects of both stimulants and stimulant-mediated dopamine release in the context of HIV and ART. Combining this system with our existing high-throughput assays, we will define the processes by which stimulants alter HIV infection and inflammation, identifying the genes, inflammatory pathways and receptors associated with these changes in both microglia and neurons and determining how these changes alter neuronal function and microglia-dopamine neuron communication.

PI_NAMEs: GASKILL, PETER JESSE (contact)

PROGRAM_OFFICER_NAME: TSAI, SHANG-YI ANNE

PROJECT_TERMS: 3-Dimensional;Acceleration;Address;antiretroviral therapy;ATAC-seq;Atlases;Automobile Driving;Behavioral;Biological Assay;Brain;Cell Culture Techniques;Cell Survival;cell type;Cells;Chromatin;Clustered Regularly Interspaced Short Palindromic Repeats;Cocaine;Coculture Techniques;Cognitive;Communication;comorbidity;confocal imaging;cytokine;Data;Data Correlations;Dendritic Spines;density;Disease;Disease Progression;Dopamine;Dopamine Receptor;dopaminergic neuron;Electrophysiology (science);Evaluation;Exposure to;Gene Expression;Gene Expression Profile;Genes;Genetic;Health;High Prevalence;high throughput analysis;high throughput screening;HIV;HIV Infections;Human;human induced pluripotent stem cells;Image;Impaired cognition;Impairment;In Vitro;in vitro activity;induced pluripotent stem cell;Infection;Inflammasome;Inflammation;Inflammatory;Intervention;knock-down;Knowledge;Macrophage;Mediating;Membrane Potentials;Methamphetamine;Microglia;Modeling;Molecular;Morphology;multi-electrode arrays;Myelogenous;Myeloid Cells;neuroAIDS;Neurobiology;Neurocognitive Deficit;Neuroimmune;neuroinflammation;Neuronal Differentiation;Neuronal Dysfunction;Neurons;Neuropathogenesis;neuropathology;neuropsychiatry;nonhuman primate;pandemic disease;patch clamp;Pathway interactions;Persons;pharmacologic;Phase;Physiological;Population;prevent;Process;Production;Protocols documentation;Publishing;receptor;Receptor Activation;response;Rest;Risk;single cell ATAC-seq;single-cell RNA sequencing;Stimulant;stimulant exposure;stimulant use;Substance abuse problem;System;Systemic disease;Testing;transcription factor;Transcription Factor AP-1;Viral

PROJECT_TITLE: Defining molecular mechanisms by which stimulant evoked dopamine drives inflammation and neuronal dysfunction in neuroHIV


ADMINISTERING_IC: HG

IC_NAME: NATIONAL HUMAN GENOME RESEARCH INSTITUTE

NIH_SPENDING_CATS: Behavioral and Social Science;Biotechnology;Clinical Research;Genetics;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Human Genome;Pediatric;Physical Rehabilitation;Prevention;Rehabilitation;Social Determinants of Health

ORG_CITY: LOUISVILLE

ORG_NAME: UNIVERSITY OF LOUISVILLE

ORG_STATE: KY

PHR: PROJECT NARRATIVE Families with children who have identified deficits in speech and/or sensory or musculoskeletal impairments without a known cause may be referred for genetic testing to find out whether there is a genetic cause. However, there is little research into how parents and caregivers use this diagnosis to inform decisions about therapeutic services, access to school services, or how a genomic diagnosis informs the practice of the community professionals who provide these services. This project will examine how a genomic diagnosis shapes the care that children receive from community professionals, including physical and occupational therapists, speech-language pathologists, special education teachers, behavior analysts, and mental health providers.

PI_NAMEs: BROTHERS, KYLE BERTRAM (contact);COOPER, GREGORY MICHAEL

PROGRAM_OFFICER_NAME: STERLING, RENE

PROJECT_TERMS: Address;Area;base;Behavior;Behavior Therapy;Caregivers;Caring;Child;Child Care;Childhood;Clinical;clinical application;clinical care;clinical diagnostics;clinical research site;cohort;Communities;community based service;Community Healthcare;Community of Practice;community setting;Complex;Diagnosis;Dimensions;Disease;Evaluation;exome sequencing;experience;Face;falls;Family;family support;Focus Groups;functional improvement;Future;Genetic;Genetic Diseases;genetic testing;genome sequencing;Genomics;Health;Health Personnel;Healthcare;Impairment;Intervention;Interview;Language;Measures;Medical;Mental Health;Mental Health Services;Musculoskeletal;National Human Genome Research Institute;Occupational Therapist;Occupational Therapy;Operative Surgical Procedures;Parents;Pathologist;pharmacologic;physical therapist;Physical therapy;policy implication;Professional Practice;Qualifying;Quality of life;Research;Resources;Rural Population;Schools;Sensory;Services;Shapes;Site;social implication;social media;Source;Special Education;Speech;Speech Therapy;Speech-Language Pathology;structural determinants;Structure;Support Groups;teacher;Technology;Testing;Therapeutic;Translating;translational potential;Underserved Population;United States Preventative Services Task Force

PROJECT_TITLE: Utility of Genomic Sequencing in Community Care Contexts


ADMINISTERING_IC: HS

IC_NAME: AGENCY FOR HEALTHCARE RESEARCH AND QUALITY

ORG_CITY: ANN ARBOR

ORG_DEPT: MISCELLANEOUS

ORG_NAME: UNIVERSITY OF MICHIGAN AT ANN ARBOR

PI_NAMEs: HIRTH, RICHARD A (contact)

PROGRAM_OFFICER_NAME: WALKER, CHIVONNE L

PROJECT_TITLE: Health Services Research Training Years 32-36


NIH_SPENDING_CATS: Clinical Research;Contraception/Reproduction;Fibroid Tumors (Uterine);Genetics;Human Genome;Women's Health Research

ORG_CITY: SAN ANTONIO

ORG_DEPT: GENETICS

ORG_NAME: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER

ORG_STATE: TX

PHR: PROJECT NARRATIVE Uterine fibroids (UFs; leiomyomas) are the most important benign neoplastic threat to women’s health worldwide. Current treatment options are limited beyond surgery, and the development of more effective medical therapies will require a better understanding of the underlying molecular etiology of UFs. Accordingly, this proposal is impactful as it suggests a novel etiologic basis for UF development through pathological reprogramming of the myometrial epitranscriptome and further offers proof of concept for therapeutic intervention using epigenetic inhibitors of tumorigenic enhancer activity driven by m6A-chromatin crosstalk. The studies proposed herein thus address and mechanistically connect two overarching issues in the field: the emerging role of the dynamic epitranscriptome in UF pathogenesis and the development of novel targeted therapies for UFs.

PI_NAMEs: AL-HENDY, AYMAN ;BOYER, THOMAS G (contact);YANG, QIWEI

PROGRAM_OFFICER_NAME: TINGEN, CANDACE M

PROJECT_TERMS: Acute;Address;Benign;Bromodomain;Catalytic Domain;Cell Death;cell growth;Cell Survival;cell transformation;Cells;Chemicals;ChIP-seq;Chromatin;Chromosomes;Chronic;comparative;Complex;Data Set;Development;Disease Progression;effective therapy;Enhancers;Epigenetic Process;epigenome;epitranscriptome;epitranscriptomics;Etiology;Expression Profiling;Fibroid Tumor;Fibrous capsule of kidney;Gene Expression;Genetic Determinism;Genetic Transcription;Growth;Habitual Abortion;Health Care Costs;histone methylation;histone modification;Homeostasis;human disease;human model;In Vitro;in vivo;Infertility;inhibitor;inhibitor therapy;insight;Knowledge;Leiomyoma;Link;Measures;Mediating;Medical;Menorrhagia;Messenger RNA;Methylation;methylome;methylomics;Methyltransferase;Modification;Molecular;Morbidity - disease rate;mouse model;mRNA Decay;mRNA Stability;mRNA Translation;Mus;mutant;Myometrial;myometrium;neoplastic;new therapeutic target;novel;Onset of illness;Operative Surgical Procedures;overexpression;Pathogenesis;Pathologic;Pathway interactions;Patients;Pelvic Pain;Phenotype;posttranscriptional;pre-clinical;Premature Labor;programs;reproductive organ;RNA;RNA Binding;RNA immunoprecipitation sequencing;RNA methylation;Role;Safety;stem cells;Testing;Therapeutic;Therapeutic Intervention;Time;Toxic effect;Transcriptional Regulation;transcriptome sequencing;Translations;Treatment Efficacy;tumor;Tumor Biology;Tumor Tissue;tumorigenic;Up-Regulation;Uterine Fibroids;Women's Health;Xenograft procedure

PROJECT_TITLE: Pathological reprogramming of the m6A epitranscriptome in uterine fibroids

STUDY_SECTION: ICER

STUDY_SECTION_NAME: Integrative and Clinical Endocrinology and Reproduction Study Section[ICER]


NIH_SPENDING_CATS: Biotechnology;Breast Cancer;Cancer;Clinical Research;Estrogen;Genetics;Precision Medicine;Women's Health Research

ORG_CITY: CHAPEL HILL

ORG_DEPT: SURGERY

ORG_NAME: UNIV OF NORTH CAROLINA CHAPEL HILL

PHR: PROJECT NARRATIVE Resistance to endocrine therapy is a leading cause of treatment failure and death in women with breast cancer. We have identified an important role for the RET receptor in resistance to endocrine therapy. In this proposal, we will investigate RET as a therapeutic target in breast cancer with mechanistic studies to inform biomarkers for future clinical trials of RET inhibitors in patients in need of better therapy.

PI_NAMEs: SPANHEIMER, PHILIP M (contact)

PROGRAM_OFFICER_NAME: BIAN, YANSONG

PROJECT_TERMS: Active Learning;Acute;Address;Award;Biological Assay;Biological Markers;biomarker identification;Breast Cancer Cell;Breast Cancer Model;Cancer Etiology;Cancer Model;career development;Cause of Death;Cell Line;Cessation of life;Chromatin;chromatin immunoprecipitation;Chronic;Clinical;Clinical Trials;Complex;Coupled;Data;Development;Development Plans;Disease;DNA Binding;Dose;effective therapy;efficacy evaluation;Endocrine;Enhancers;Ensure;Environment;Epigenetic Process;ERBB2 gene;Estrogen receptor positive;Estrogen Receptors;Experimental Designs;Funding;Future;Gene Expression Regulation;Genetic Transcription;glial cell-line derived neurotrophic factor;Goals;Growth;hormone therapy;Human;improved outcome;in vivo;inhibitor;inhibitor therapy;K-Series Research Career Programs;knock-down;Knowledge;Lead;Malignant Breast Neoplasm;Malignant Neoplasms;Mammary Neoplasms;MAP Kinase Gene;Mass Spectrum Analysis;MCF7 cell;Mediating;meetings;Mentors;Methylation;Modeling;Modification;Molecular Biology;Molecular Genetics;novel therapeutics;Organoids;Outcome;overexpression;patient derived xenograft model;Patient Selection;Patient-Focused Outcomes;Patients;Phosphotransferases;Physicians;preclinical efficacy;Primary Neoplasm;programs;Proliferating;promoter;Promoter Regions;proteogenomics;Proteomics;proto-oncogene protein c-ret;Protocols documentation;receptor;receptor binding;Recurrent tumor;Regulatory Element;Research;Research Personnel;Resistance;response;response biomarker;RET inhibition;Role;Scientific Advances and Accomplishments;Scientist;Signal Pathway;Signal Transduction;Site;Small Interfering RNA;Structure;Sulfides;Surgical Oncologist;symposium;T47D;Tamoxifen;targeted treatment;Testing;TFAP2C gene;Therapeutic;therapeutic target;Therapeutic Uses;therapy resistant;Time;Training;Transcriptional Regulation;translational model;translational research program;Treatment Failure;treatment response;tumor;tumor growth;Woman;Women's mortality;Work;Xenograft Model;Xenograft procedure

PROJECT_TITLE: Repurposing RET Inhibitors for Endocrine Resistant Breast Cancer